Bayesian hierarchical methods for network meta-analysis by Zhang, Jing
Bayesian Hierarchical Methods for Network
Meta-Analysis
A DISSERTATION
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL
OF THE UNIVERSITY OF MINNESOTA
BY
Jing Zhang
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE DEGREE OF
Doctor of Philosophy
Advised by Haitao Chu
July, 2014
c© Jing Zhang 2014
ALL RIGHTS RESERVED
Acknowledgements
I owe the greatest debt of gratitude to my advisor, Dr. Haitao Chu, for his patient
guidance, support, and encouragement. Dr. Haitao Chu has been a great mentor, role
model, and friend, all the way from my master study, through to completion of my PhD
degree. His guidance has made this a wonderful and rewarding journey. I would like
to send a warm and well-deserved thank you to my advisor Dr. Haitao Chu for always
being there for me whenever I need advice. Dr. Bradley P. Carlin’s intellectual heft
is matched only by his genuinely good nature and down-to-earth humility, and I am
truly fortunate to have had opportunity to work with him. He is indeed an inspiration
for me. Many thanks also go to Dr. James D. Neaton and Dr. Beth A. Virnig, who
are my committee members, for their friendly guidance, thought-provoking suggestions,
and invaluable input. In a similar vein, I’d like to recognize Drs. Cavan Reilly, William
Thomas, and Wei Pan for the contributions that each of them made to my intellectual
growth during my years of study at the University of Minnesota. I am also grateful to my
undergraduate professor, Dr. Jing Chen, for her generosity, guidance, and continuous
emotional support.
I also want to thank my parents and my sister for supporting me, believing in me,
and loving me throughout my 5 years here at UMN. Dad and Mom, thank you so much
for teaching me respect, confidence, and proper etiquette. Thank you for letting me
find my own way and be persistent to achieve my goal. Finally, special thanks to my
wonderful husband for showing me the real happiness in life. I can face anything because
he is by my side. I cannot find words to utter but I just want to say Thank you darling!
i
Dedication
This dissertation is dedicated to my family, especially
to my brilliant and outrageously loving and supportive husband, Yiping Yuan;
to my always encouraging and supportive parents, Aibao and Chunhua Zhang,
and parents-in law, Zhongwen Yuan and Li Cao.
to my exuberant and sweet younger sister, Lin Zhang.
ii
Abstract
In clinical practice, and at a wider societal level, treatment decisions in medicine need
to consider all relevant evidence. Network meta-analysis (NMA) collectively analyzes
many randomized controlled trials (RCTs) evaluating multiple interventions relevant to
a treatment decision, expanding the scope of a conventional pairwise meta-analysis to
simultaneously handle multiple treatment comparisons. NMA synthesizes both direct
information, gained from direct comparison for example between treatments A and C,
and indirect information obtained from A versus B and C versus B trials, and thus
strengthens inference.
Under current contrast-based (CB) methods for NMA of binary outcomes, which
do not model the baseline risks and focus on modeling the relative treatment effects,
the patient-centered measures including the overall treatment-specific event rates and
risk differences are not provided, creating some unnecessary obstacles for patients to
comprehensively understand and trade-off efficacy and safety measures. Many NMAs
only report odds ratios (ORs) which are commonly misinterpreted as risk ratios (RRs)
by many physicians, patients and their care givers. In order to overcome these obstacles
of the CB methods, a novel Bayesian hierarchical arm-based (AB) model developed
from a missing data perspective is proposed to illustrate how treatment-specific event
proportions, risk differences (RD) and relative risks (RR) can be computed in NMAs.
Since most of the trials in NMA only compare two of the treatments of interest,
the typical data in a NMA managed as a trial-by-treatment matrix is extremely sparse,
like an incomplete block structure with serious missing data problems. The previously
proposed AB method assumes a missing at random (MAR) mechanism. However, in
RCTs, nonignorable missingness or missingness not at random (MNAR) may occur due
to deliberate choices at the design stage. In addition, those undertaking an NMA will
often selectively choose treatments to include in the analysis, which will also lead to
nonignorable missingness. We then extend the AB method to incorporate nonignorable
missingness using selection models method.
Meta-analysts undertaking an NMA often selectively choose trials to include in the
analysis. Thus inevitably, certain trials are more likely to be included in an NMA. In
iii
addition, it is difficult to include all existing trials that meet the inclusion criteria due to
language barriers (i.e., some trials may be published using other languages) and other
technical issues. If the omitted trials are quite different from the ones we include, then
the estimates will be biased. We obtain empirical evidence on whether these selective
inclusions of trials can make a difference in the results, such as treatment effect estimates
in an NMA setting, using both the AB and CB methods.
In the opposite direction of the fact that some trials which should have been included
but are omitted, some trials may appear to deviate markedly from the others, and thus
be inappropriate to be synthesized. we call these trials outlying trials or trial-level
outliers. To the best of our knowledge, while the key NMA assumptions of inconsistency
and heterogeneity have been well-studied, few previous authors have considered the
issue of trial-level outliers, their detection, and guidance on whether or not to discard
them from an NMA. We propose and evaluate Bayesian approaches to detect trial-level
outliers in the NMA evidence structures.
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Chapter 1
Introduction
Meta-analysis, a statistical technique to assess treatment effects quantitatively by com-
bining the results from several independent studies [2, 3], is now a hallmark of Com-
parative Effectiveness Research (CER) and Evidence Based Medicine (EBM) [4][5], two
rapidly growing fields whose objective is to assess how various medical interventions re-
sult in improved health care outcomes. CER is the study of two or more approaches to
a health problem to determine which one results in better health outcomes [4]. EBM is
defined as the conscientious, explicit and judicious use of current best evidence in mak-
ing decisions about the care of individual patients [6][7]. Both CER and EBM require
rigorous and systematic analysis of published literature to identify, appraise, select and
synthesize all high quality research evidence relevant to a particular question.
However, traditional meta-analysis techniques can only enable a pairwise compar-
ison at a time (usually, between placebo and an experimental drug). To understand
comprehensively the performance of all possible interventions and to facilitate decision
making, we have to compare them to one another simultaneously, not just to placebo or
some particular standard treatment. Network meta-analysis (NMA), a meta-analytic
statistical method, expands the scope of conventional pairwise meta-analysis to simulta-
neously compare multiple treatments in a connected network by synthesizing direct and
indirect information [8]. Thus NMA provides the cornerstone for the recent explosion
of CER and EBM.
1
2Figure 1.1: Illustration of direct and indirect information
1.1 Background and current development
We now first introduce the evidence synthesis process of NMA with a simple three
treatment network as is shown in Figure 1.1 adapted from Li et al. [9]. Suppose the
primary interest is the comparison of A versus C, NMA techniques allow us to combine
evidence from trials directly comparing treatments A and C (AC trials), trials directly
comparing A and B (AB trials), and trials directly comparing B and C (BC trials). AC
trials are direct information while AB and BC trials are indirect information.
There is a broad consensus that the “best” evidence on the effect of treatment C
relative to treatment A is provided by head-to-head trials, which provide a “direct”
estimate. However, even if this is accepted, several reasons can be advanced for taking
a wider view of what the legitimate evidence base should be. First, it may be that
there are no A vs C trials, but that instead an “indirect” estimate can be formed from
the results of A vs B and B vs C trials. For example, two new active treatments
may have been compared with placebo, or to an established standard treatment, but
manufacturers have proved reluctant to carry out the head-to-head comparisons that
would be of most clinical interest. A second reason might be that, even if direct AC
evidence exists, it may be sparse; the volume of indirect evidence can be much greater.
This is, in fact, a very common situation. In a nutshell, by incorporating indirect
evidence, NMA enables comparison of interest even if there is no direct information and
strengthens inference when direct information is available.
3There is by now a considerable literature for NMA, see, for example, by several work-
ing groups, including the Pharmaceutical Benefits Advisory Committee in Australia [10],
the Canadian Agency for Drugs and Technologies in Health [11], and the National In-
stitute for Health and Clinical Excellence (NICE) in the United Kingdom [12]. The
most popular and to current method is the contrast-based (CB) Bayesian hierarchical
modeling [13, 14, 15, 16, 17, 18]. This approach chooses one of the treatments as the
baseline and focuses on estimating the relative treatment effects, e.g. the odds ratio
(OR). Lu and Ades [16, 17] proposed Bayesian NMA models under the CB framework
for a binary outcome and gained popularity in this field, and subsequently the NICE
group (e.g., Dias et al. [19] and some others [20, 21, 22]) extended these models to other
types of outcomes (e.g., continuous and count data). In addition, Salanti et al. [23]
introduced an arm-based (AB) parameterization for NMAs and compared it with the
CB parameterization.
There are two major issues for NMA: heterogeneity and inconsistency [15, 16, 17,
24, 25, 26, 27]. Heterogeneity aims to assess the dispersion of effect sizes from study to
study, then take them into account when interpreting the data [28]. Since each study
is conducted under different conditions and populations, study-specific effect sizes may
vary even when they are drawn from an underlying population of study effects that has a
common mean. If the effect size is consistent, then we will usually focus on the summary
effect; if the effect size varies modestly, then we might still report the summary effect
but note that the true effect in any given study could be somewhat lower or higher than
this value; if the effect varies substantially from one study to the next, our attention
will shift from the summary effect to the random effects, or even the dispersion itself.
Random-effects models are usually used to take charge of heterogeneity.
Evidence inconsistency is usually defined, informally, as the disagreement between
the direct and indirect point estimates of a particular comparison of treatments within a
broader network of evidence. For simplicity, let us again use the three treatment network
in Figure 1.1. This simple network has a single triangular closed loop of evidence shown
in Figure 1.2. In the CB framework, consistency dAB = dCB − dCA is usually assumed,
where dhk represents the relative treatment effect between treatment h and treatment
k. Inconsistency arises when this equality does not hold [15, 17, 29, 24, 30, 31]. In
contrast, in the AB framework, instead of loop-based definition, Zhao et al. [32] used
4Figure 1.2: Loop for inconsistency
fixed and random effects to define and detect inconsistency.
1.2 Overview of the contribution in this thesis
A limitation of reporting for many current contrast-based NMA methods for binary out-
comes is that the only summary statistic usually reported is OR[33][34][35][36][37][38][39][40][41].
ORs are often mistakenly thought as RRs by physicians, patients and their care givers,
although it is well-known that RRs and ORs diverge when events are common (i.e.,
event rates are higher than 10%) [42][43][6][44]. Absolute measures including treatment-
specific event rates and RDs contain important information that cannot be expressed
by ORs [28]. Thus both relative measures and absolute measures should be reported
and reporting only OR is not proper. However, to the best of our knowledge, only a
few published NMAs [45][46] have reported RR, and none have reported the treatment-
specific event rates and RDs. This limitation in reporting arises because many current
statistical approaches and software [47][48][49][50][51][52][53][54][55] are not capable of
estimating treatment-specific response proportions and summary statistics such as the
risk difference (RD) and RR. We instead propose a novel arm-based Bayesian hierar-
chical method from the missing data perspective [8]. More specifically, we treat the
sparsity as missing at random (MAR), which is totally different from Salanti et al. [23].
5Our proposed method provides both direct estimates including event rates and RDs and
indirect estimates including RRs and ORs.
A thorny problem in NMA involves nonignorable data missingness. It can happen
due to deliberate study design. For example, clinicians often select treatments that
have appeared to be more effective based on previous RCTs or their own personal
medical experience, which may lead to a higher probability of missingness for relatively
ineffective treatments. Another situation that can lead to nonignorable missingness
is when meta-analysts undertaking an NMA selectively choose treatments to include
in the analysis. For example, some NMAs exclude placebo or “no treatment” from
consideration because it is sometimes believed that placebo trials vary over time; or
are set in favorable conditions to appease regulatory authorities [56]. Other NMAs
may include only the treatments available in particular location or time period, only
those of perceived dose relevance, or (often in the case of industry submissions to health
technology assessment bodies) only specific competing treatments [57][58]. In these
cases, simply ignoring missingness (as the CB method does) or considering all missing
data to be MAR as [8] can lead to bias [59]. To handle this problem, we jointly model
the data and the missing indicator using a selection models approach.
A very interesting paper by Mills et al. [58] investigated empirically the effects of ex-
cluding treatments from NMA. It concluded that excluding treatments sometimes could
have important effects on the results and could diminish the usefulness of the research to
clinicians if important comparisons were missing. In the same vein, those undertaking
an NMA will often selectively choose trials to include in the analysis. Inevitably, certain
trials are more likely to be included in an NMA. In addition, it is difficult to include all
existing trials that meet the inclusion criteria due to language barriers (i.e., some trials
may be published using other languages) and other technical issues. Intuitively, if the
omitted studies are a random subset of all relevant studies, the failure to include these
studies will only result in less information, wider confidence intervals, and less powerful
tests, but will not have any systematic impact on the NMA points estimates. However,
if the omitted studies are systematically different from the ones we include, then these
estimates will be biased. We thus obtained empirical evidence on whether these selec-
tive inclusions of trials could make a difference in the results such as treatment effect
estimates in an NMA, where both the AB and CB methods were applied.
6After investigating the influence of omission of trials that should have been included,
we next study trials that are included but appear to deviate markedly from the oth-
ers, and thus might actually be inappropriate to be synthesized. We call these trials
“outlying” trials. To the best of our knowledge, while the key NMA assumptions of
inconsistency and heterogeneity have been well-studied, few previous authors have con-
sidered the issue of trial-level outliers, their detection, and guidance on whether or not
to discard them from an NMA. We thus propose four outlier detection measures for
NMA in order to identify outlying trials and suggest to leave them out of the evidence
synthesis.
The remainder of this thesis is structured as follows. First, Chapter 2 introduces the
novel arm-based Bayesian hierarchical method under the missing at random assump-
tion. We compare our approach to other alternative methods using two hypothetical
NMA data sets, and then re-analyze two published network meta-analyses and show how
more comprehensive and proper summary statistics can be reported using the proposed
method. Chapter 3 presents our Bayesian selection models method aiming to handle the
nonignorable missingness problem. We compare the proposed method, which models the
observed data and missing indicator simultaneously, with the methods that consider the
missingness as missing completely at random (MCAR) or MAR. In Chapter 4, we inves-
tigate empirically the impact of excluding trials that should have been included under
both AB and CB framework. Chapter 5 proposes and evaluates Bayesian approaches to
detect trial-level outliers in NMA evidence structures. The four detection measures are:
relative distance (RD), Bayesian standardized trial residual (STR), Bayesian p-value,
and scale mixtures of normals (SMN). Finally, Chapter 6 summarizes our findings and
discusses potential areas for future work.
Chapter 2
Network meta-analysis of
randomized clinical trials:
reporting the proper summaries
In this chapter, we introduce the novel arm-based Bayesian hierarchical method which
enables proper summaries, including direct summaries such as event rates and RDs,
and indirect summaries such as RRs and ORs. This chapter begins in Section 2.1
with the background of reporting in NMAs. Section 2.2 provides details of this arm-
based Bayesian NMA method and also introduces the existing CB method. Section 2.3
presents our data analysis results for two hypothetical data sets, aiming to compare the
AB method with the CB method and traditional pairwise meta-analysis method. It also
presents the re-analysis of two published NMAs. Section 2.4 concludes with a summary
and discussion of limitations.
2.1 Background of reporting in NMA
To the best of our knowledge, only a few published NMAs [45][46] have reported RR, but
none have reported the treatment-specific event rates and RDs. They focus on treatment
contrasts where one of the arms of each study is chosen as ”baseline”. Since many
NMAs do not have a common control arm such as a placebo or standard intervention
7
8and different trials may have different ”baselines”, specifying a common distribution for
baseline groups is generally not interpretable. Thus, many current NMA methods treat
the underlying baseline risks as nuisance parameters and therefore fail to estimate the
treatment-specific response proportions.
Although a few [51][22][60][61][62] discussed the transformation from the ORs to
RRs and RDs, they depend on a strong assumption that either the event rate in a
reference treatment group can be accurately estimated from some external data, or
by summarizing only trials with the reference arm with a separate (random effects)
model. In many cases, such external data are not available limiting the applicability
of the former approach. Furthermore, even if some external data are available, it may
come from a different population than what the NMA may represent. From the theory
of missing data analysis [63], these current NMA methods are unbiased only under a
strong assumption of missing completely at random (i.e., all trials randomly choose to
include or not include the reference arm).
2.2 Statistical methods
Consider a collection of RCTs i = 1, 2, . . . , I, each of which only includes a subset of
the complete collection of K treatments. Let ki be the number of treatments, and Si
be the set of treatments that are compared in the ith trial. Trials with ki ≥ 3 are called
“multi-arm” trials, in contrast to ki = 2 for “two-arm” trials. For our binary data, let
Di = (yik, nik), k ∈ Si, i = 1, 2, . . . , I denote the available data from the ith trial, where
nik is the total number of subjects and yik is the total number of responses for the k
th
arm in the ith trial. The corresponding probability of response is denoted by pik. In
this section, we first briefly review the most commonly used contrast-based approach,
then present our novel arm-based approach illustrating how to accurately estimate the
overall treatment-specific event rates from the perspective of missing data analysis. At
last, we evaluate the performance of a few alternative methods using two hypothetical
examples.
92.2.1 The contrast-based (CB) approach
Let bi be the specified “baseline” treatment for the i
th trial, commonly denoted as b for
simplicity. Let Xik = 1 if k 6= b and Xik = 0 if k = b. The The most commonly used
CB models use the following Bayesian hierarchical model [53],
yik
ind∼ Bin(nik, pik), i = 1, . . . , I, k ∈ Si,
logit(pik) = µi +Xikδibk, δibk
ind∼ N(dbk, σ2bk),
dhk = dbk − dbh,
Corr(δibh, δibk) = γ
b
hk, b 6= h 6= k ∈ Si.
where µi is the specified baseline effect that is commonly regarded as a nuisance pa-
rameter; Xik is the indicator for baseline, taking value 0 when k = b and 1 when k 6= b;
b(i) is the specified baseline treatment in trial i, commonly denoted as b for simplicity
as above; and δibk represents the contrast between treatment k and b for the i
th trial
and is assumed to be a random effect with a normal distribution with mean dbk and
variance σ2bk. dhk = dbk − dbh represents consistency and γ(b)hk represents the correlation
between δibh and δibk.
2.2.2 The arm-based (AB) approach
We view the analytic challenges associated with NMA from the perspective of missing
data analysis [63][59][64][65][66]. The basic idea of this arm-based approaches to NMA
(which focus on modeling the event proportions for each treatment arm), in contrast to
the contrast-based approaches (which focus on modeling the relative treatment effects,
e.g., ORs, comparing treatments), has been briefly discussed by Salanti et al. [67], but
thoroughly not from the missing data perspective. When viewed from this perspective,
the proportion of patients responding to each treatment and associated summary statis-
tics such as the RD, RR and OR can be estimated. Specifically, we assume that each
study hypothetically compares all treatments, many of which are missing by design and
thus can be considered as missing at random [59].
Specifically, we consider the multivariate Bayesian hierarchical mixed model (MBHMM),
which extend the bivariate generalized linear mixed model for the meta-analysis of com-
parative studies of two arms [68]. First, we assume conditional on Pi = pik, the elements
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yik of Y = yik are independently binomially distributed with probability mass function
P (Yi = yi) ∼
∏
k∈Si
(pik)
yik(1− pik)nik−yik . (2.1)
Second, we assume a multivariate normal distribution (MVN) for pik on a probit
transformed scale. In the absence of any individual level covariates, the model is speci-
fied as
Φ−1(pik) = µk + σkνik, (νi1, . . . , νiK)T ∼MVN(0, RK), (2.2)
where Φ() is the standard normal cumulative distribution function, (µ1, . . . , µK) are
treatment-specific fixed effects, RK is a positive definite correlation matrix with off-
diagonal elements ρk1k2 , σk is the standard deviation for the random effects νik. Let
diag(σ1, . . . , σK) be a diagonal matrix with elements σi, the covariance matrix is thus
ΣK = diag(σ1, . . . , σK) × RK × diag(σ1, . . . , σK). Here, σk captures trial-level hetero-
geneity in response to treatment k, and Rk captures the within-study dependence among
treatments. The population-averaged event rate can then be calculated, for example
with the probit link, as
pik = E(pik|µk, σk) =
∫ ∞
−∞
Φ(µk + σkz)φ(z)dz = Φ(µk/
√
1 + σ2k), k = 1, . . . ,K, (2.3)
where Φ() is the standard normal cumulative density function and φ() is the stan-
dard normal density function. We can also use some other link functions, for ex-
ample logit link, under which condition, the population-averaged event rate is pik ≈
expit(µk/
√
1 + C2σ2k), where C = 16
√
3/(15pi) and expit(x) = ex/(1 + ex). The
marginal OR, RR, and RD are defined as ORkl = [pik/(1 − pik)]/[pil/(1 − pil)], RRkl =
pik/pil and RDkl = pik−pil for a pairwise comparison between treatments k and l (k 6= l).
Since improper prior distributions may lead to an improper posterior in some com-
plex models [69][70], we selected minimally informative but proper priors. Specifically,
we chose a weakly informative prior N(0, τ2µ) for µk with τ
2
µ = 1000, and a Wishart prior
for the precision matrix, i.e., Σ−1K ∼W (V, n), where the degrees of freedom n = K, V is
a known K×K matrix with diagonal elements equal 1.0, and off-diagonal elements equal
0.005. It turned out that the above prior corresponded to a 95% CI of 0.45 to 32.10
for the standard deviation parameters and a 95% CI of 1.00 to 1.00 for the correlation
parameters, which is computed via simulations using the R function rWishart(). The
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Washart distribution is the conjugate prior of the precision matrix of a multivariate-
normal random vector in Bayesian statistics, which facilitates the computation of the
unstructured posterior covariance matrix.
We implemented our method within a fully Bayesian framework using Markov chain
Monte Carlo (MCMC) methods with the WinBUGS software [71][72]. Weakly informa-
tive priors were used and posterior samples were drawn using Gibbs and Metropolis-
Hastings algorithms [73][73] with convergence assessed using trace plots, sample auto-
correlations, and other standard convergence diagnostics [74][75]. A generous burn-in
period of 1,000,000 iterations was used, with 1,000,000 subsequent iterations retained for
accurate posterior treatment effect estimates. By borrowing information across multiple
treatments, the multivariate Bayesian hierarchical mixed model that we utilize reduces
potential bias when missing is not completely at random, compared to a naive approach
of estimating population-averaged treatment-specific event proportions or rates based
solely on studies that used a particular treatment. With this Bayesian approach, we
used the 95% posterior credible intervals to assess statistical significance (according to
whether the CI included the null value) instead of p-values [76]. The corresponding
WinBUGS code is presented in the appendix.
2.2.3 Evaluation of different approaches
To investigate the performance of the proposed arm-based multivariate Bayesian hierar-
chical mixed model, we create two hypothetical network meta-analysis data sets under
either a homogenous relative risk (RR) or a homogenous rate difference (RD) assump-
tion. Each network meta-analysis includes 11 trials and 3 treatment arms. Because in
a typical network meta-analysis, most trials only compare a subset of all treatments of
interest, we let two trials compare all three treatments, and three trials each comparing
A and B, B and C, A and C, respectively. The total numbers of patients are equal to
1000 for arm A, 2000 for arm B, and 500 for arm C in all trials. The response rates for
arm A are assigned from a uniform distribution ranging from 0.10 to 0.40 in ascending
order for the 11 trials. The corresponding numbers of responses for arm B and C in
each trial are assigned based on a fixed RR or a fixed RD assumption. Specifically, the
RR of B vs. A is 1.50 and C vs. A is 2.00 under the fixed RR assumption, and the RD
of B vs. A is 15% and C vs. A is 25% under the fixed RD assumption. To simplify
12
illustration, we ignore the random sampling error and assume the number of events is
equal to the response rates multiplied by the total number of patients.
We analyzed the above two hypothetical data using four methods. The first is based
on Cochran-Mantel-Haenszel procedure with estimates of the log OR and variance as
discussed in Yusuf et al. (we refer to this as Petos method) [77]. With this fixed effect
method, inferences are based on the direct head-to-head pairwise comparisons. The
second and third methods are the Lu & Ades contrast-based network meta-analysis
method under either a homogeneous variance (i.e., the HOM model) or an unstructured
heterogeneous variance assumption (i.e., the ID model)35. It combines the direct and in-
direct evidence, but it is not able to estimate the population-averaged treatment-specific
event rates. The fourth is the arm-based network meta-analysis method that we have
proposed. By borrowing information across treatment arms, it is able to estimate the
treatment-specific event rates. The hypothetical data and the assumptions underlying
these four methods are given in the web appendix wTable 1 and wTable 2, respectively.
2.3 Results
2.3.1 Comparison of four methods with hypothetical data
Table 2.1 presents the ORs based on the pairwise head-to-head comparisons for each
hypothetical trial. The difference between the mean ORs from the observed data versus
the mean ORs from the full data illustrates the potential bias of summarizing treatment
effects based only on trials with particular treatment arms, i.e., the direct head-to-head
comparisons. As evidenced by these two examples, the direction of bias can be either
toward the null or away from the null, depending on the underlying data generating and
missing data generating mechanisms, which limits the application and generalizability
of methods based on direct head-to-head comparisons. For example, the true mean OR
of B vs. A under a fixed RR assumption is 1.85, as compared to the mean OR of 1.66
based on the available direct head-to-head comparisons. The true mean OR of B vs. A
under a fixed RD assumption is 2.15, as compared to the mean OR of 2.45 based on the
available direct head-to-head comparisons.
Table 2.2 compares the population-averaged treatment-specific event rate estimates
from the observed data vs. that from the full data based on the new method. It shows
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Table 2.1: The odds ratios based on pairwise head-to-head comparisons
I. Fixed RR II. Fixed RD
B vs. A C vs. A C vs. B B vs. A C vs. A C vs. B
Trial 1 1.59 2.25 1.42 3.00 4.85 1.62
Trial 2 1.62 2.35 1.45 2.60 4.10 1.58
Trial 3 1.66 2.47 1.49 2.36 3.65 1.55
Trial 4 1.70 2.61 1.54 2.20 3.35 1.53
Trial 5 1.75 2.79 1.60 2.08 3.14 1.51
Trial 6 1.80 3.00 1.67 2.00 3.00 1.50
Trial 7 1.86 3.27 1.76 1.94 2.90 1.49
Trial 8 1.93 3.63 1.88 1.90 2.83 1.49
Trial 9 2.02 4.12 2.04 1.87 2.79 1.50
Trial 10 2.12 4.85 2.28 1.84 2.78 1.51
Trial 11 2.25 6.00 2.67 1.83 2.79 1.52
Mean OR1 1.66 2.90 1.97 2.45 3.54 1.54
Mean OR2 1.85 3.40 1.80 2.15 3.29 1.53
OR=Odds Ratio; RR=Relative Risk; RD=Rate Difference; Mean OR1 is the
mean of ORs from the observed data assuming the italic cells are not available as
in many NMAs; mean OR2 is the mean of ORs from the full data assuming all
the italic cells are observed and available.
that with this approach, estimates of the population-averaged treatment-specific event
rates are nearly unbiased. In addition, the information loss due to missing data is mostly
recovered as evidenced by the similarity of the length of the posterior credible intervals.
Table 2.3 compares the relative treatment effect estimates for the four methods using
the observed data (which assume that the greyed cells in web appendix wTable 1 are
not available as in many NMAs) and the full data (which assume that each trial has
three arms and there is no missing arms), respectively. Under the hypothetical data
generating mechanisms, all 4 model assumptions are incorrect, and the true ORs are
not well defined. Thus, we choose the estimates from the full data as the true ORs
under each model assumption. The closer the estimates from the observed data are
to that from the full data, the less bias of the method. Under both fixed RR and
fixed RD assumptions, Petos method is potentially biased since it incorporates only
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Table 2.2: Population averaged event rate estimates under fixed RR and RD assump-
tions
Event Rates Treatment A Treatment B Treatment C
Fixed RR True 0.25 0.375 0.50
Observed data 0.25(0.19,0.34) 0.37(0.28,0.46) 0.50(0.38,0.61)
Full data 0.25(0.19,0.31) 0.37(0.29,0.45) 0.50(0.38,0.59)
Fixed RD True 0.25 0.40 0.50
Observed data 0.24(0.18,0.33) 0.40(0.33,0.48) 0.50(0.43,0.57)
Full data 0.25(0.19,0.32) 0.40(0.34,0.46) 0.50(0.43,0.56)
Results based on the proposed method; OR = Odds Ratio; RR = Relative Risk;
RD = Rate Difference.
the direct information (the available head-to-head comparisons of two treatments). For
example, under the fixed RR assumption, the estimated OR from Petos method is 1.63
comparing treatment B vs. A using the observed data set, while the corresponding OR
from the full data set is 1.83 illustrating some biases. Lu & Ades contrast-based method
shows potential biases, which is consistent with the results from simulation studies55.
For example, under the fixed RR assumption, the estimated ORs of B vs. A from the
observed data are 1.60 (95% CI 1.39, 1.81) and 1.66 (1.44, 1.85) under the Lu and
Ades HOM and ID model assumptions, while the corresponding estimated ORs from
the full data is 1.87 (1.66, 2.09) and 1.88 (1.75, 2.00), respectively. In contrast, using
our proposed arm-based method, estimates for the ORs, RRs and RDs under both fixed
RR and RD assumptions are nearly unbiased.
2.3.2 Re-analyses of two network meta-analyses recently published in
The Lancet
Comparative efficacy and acceptability of 12 antidepressants
Cipriani et al. [34] Comprehensively summarized results of 117 randomized controlled
trials (25,928 participants) from 1991 to 2007, and compared 12 new-generation an-
tidepressants in terms of efficacy and acceptability in acute-phase treatment of major
depression. The main outcomes were the proportions of patients who responded to a
treatment or discontinued the allocated treatment (dropped out). Response was defined
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as the total number of patients who had a reduction of at least 50% from baseline score
at 8 weeks on the Hamilton depression rating scale (HDRS).
Table 2.4 presents a summary of the efficacy results using the proposed method. A
similar table that only cited ORs and 95% CIs was reported by Cipriani et al6. The
population-averaged treatment-specific response proportions are given in the diagonal
entries in the table. These proportions range from 0.48 (95% CI 0.41 to 0.55) for
reboxetine (REB) to 0.62 (95% CI 0.57 to 0.67) for mirtazapine (MIR). The upper and
lower triangular panels report the RRs and RDs of all pairwise comparisons. Table
2.6 summarizes the treatment discontinuation proportions using the proposed method
in the same format as the efficacy results. The population-averaged treatment-specific
dropout rates (diagonal entries in the table) range from 0.21 for citalopram (CIT) (95%
CI 0.17 to 0.26) and escitalopram (ESC) (95% CI 0.17 to 0.26) to 0.29 for REB (95%
CI 0.23 to 0.37), fluoxetine (FVX) (95% CI 0.23 to 0.37), and milnacipran (MIL) (95%
CI 0.21 to 0.37).
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Table 2.3: Relative treatment effect estimates under fixed RR and RD
Observed Data Full Data
B vs. A C vs. A C vs. B B vs. A C vs. A C vs. B
I. Fixed RR
OR
Peto
1.63 3.06 1.93 1.83 3.36 1.78
(1.50,1.77) (2.74,3.41) (1.75,2.13) (1.74,1.93) (3.13,3.61) (1.67,1.90)
HOM
1.60 3.18 1.99 1.87 3.29 1.76
(1.39,1.81) (2.75,3.64) (1.73,2.31) (1.66,2.09) (2.89,3.71) (1.50,2.06)
ID
1.66 3.23 1.98 1.88 3.30 1.76
(1.44,1.85) (2.66,4.07) (1.56,2.44) (1.75,2.00) (2.78,3.90) (1.48,2.09)
New
1.72 2.97 1.74 1.78 2.96 1.66
(1.29,2.30) (2.20,4.12) (1.34,2.24) (1.52,2.09) (2.38,3.63) (1.40,1.96)
RR True 1.50 2.00 1.33 1.50 2.00 1.33
New
1.45 2.00 1.33 1.50 2.00 1.33
(1.18,1.78) (1.63,2.41) (1.19,1.57) (1.34,1.66) (1.77,2.21) (1.22,1.45)
II. Fixed RD
OR
Peto
2.20 3.45 1.54 1.99 3.23 1.53
(2.03,2.37) (3.10,3.83) (1.41,1.69) (1.89,2.09) (3.01,3.46) (1.44,1.63)
HOM
2.28 3.36 1.47 2.06 3.15 1.53
(2.08,2.54) (3.03,3.76) (1.32,1.63) (1.94,2.20) (2.92,3.41) (1.42,1.65)
ID
2.31 3.40 1.47 2.07 3.16 1.53
(2.07,2.59) (3.00,3.93) (1.30,1.66) (1.94,2.21) (2.91,3.42) (1.41,1.65)
New
2.09 3.17 1.52 1.99 2.98 1.50
(1.48,2.85) (2.28,4.31) (1.19,1.95) (1.66,2.36) (2.44,3.59) (1.28,1.75)
RD True 0.15 0.25 0.10 0.15 0.25 0.10
New
0.16 0.25 0.10 0.15 0.25 0.10
(0.09,0.22) (0.19,0.32) (0.04,0.16) (0.11,0.18) (0.21,0.28) (0.06,0.14)
Note: HOM represent the contrast-based NMA with a homogeneous variance as-
sumption; ID represents the contrast-based NMA with an unstructured heteroge-
neous variance assumption; New represnts our proposed arm-based NMA with an
unstructured heterogeneous variance assumption.
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Table 2.4: Population averaged responses rates (proportions), relative risks, and risk differences of the 12 antidepressants
BUP CIT DUL ESC FLU FVX MIL MIR PAR REB SER VEN
BUP 0.570 1.020 1.086 0.946 1.070 1.087 1.099 0.921 1.040 1.189 0.970 0.953
(0.522,0.615) (0.901,1.164) (0.937,1.268) (0.853,1.049) (0.972,1.175) (0.944,1.263) (0.897,1.358) (0.824,1.030) (0.940,1.149) (1.015,1.417) (0.877,1.072) (0.865,1.052)
CIT 0.011 0.558 1.065) 0.927 1.049 1.065 1.077 0.903 1.019 1.166∗ 0.951 0.935
(-0.059,0.084)(0.499,0.615) (0.908,1.250) (0.830,1.030) (0.937,1.161) (0.918,1.240) (0.869,1.337) (0.795,1.018) (0.905,1.138) (0.987,1.384) (0.843,1.062) (0.829,1.043)
DUL 0.045 0.034 0.524 0.871 0.984 1.001 1.012 0.848 0.957 1.094∗ 0.893∗ 0.878∗
(-0.037,0.125)(-0.053,0.118) (0.457,0.595) (0.757,0.992) (0.855,1.124) (0.839,1.196) (0.804,1.275)(0.727,0.982) (0.834,1.088) (0.905,1.336) (0.770,1.029) (0.757,1.009)
ESC -0.033 -0.044 -0.078 0.602 1.131 1.150 1.162 0.974 1.099 1.258 1.025 1.008
(-0.092,0.028)(-0.105,0.017)(-0.150,-0.005)(0.557,0.646) (1.040,1.229) (1.005,1.328) (0.950,1.430) (0.878,1.081) (1.007,1.199) (1.080,1.490) (0.935,1.125) (0.921,1.103)
FLU 0.037 0.026 -0.008 0.070 0.533 1.016 1.027 0.861 0.972 1.112∗ 0.907 0.891
(-0.015,0.090)(-0.034,0.084) (-0.078,0.065) (0.022,0.118) (0.499,0.564) (0.899,1.163) (0.854,1.248)(0.789,0.943) (0.904,1.045) (0.964,1.302) (0.840,0.982)(0.832,0.957)
FVX 0.046 0.034 0.001 0.078 0.008 0.524 1.010 0.848 0.957 1.094∗ 0.892∗ 0.877
(-0.032,0.123)(-0.047,0.114) (-0.092,0.094) (0.003,0.153) (-0.059,0.076) (0.459,0.590) (0.817,1.257)(0.735,0.968) (0.834,1.084) (0.907,1.327) (0.776,1.017) (0.762,1.000)
MIL 0.051 0.040 0.006 0.084 0.014 0.005 0.518 0.838 0.946 1.083∗ 0.882 0.868
(-0.064,0.155)(-0.080,0.147) (-0.119,0.121) (-0.031,0.185) (-0.091,0.106) (-0.111,0.113) (0.425,0.626) (0.680,1.024) (0.775,1.144) (0.851,1.379) (0.719,1.074) (0.709,1.054)
MIR -0.049 -0.060 -0.094 -0.016 -0.086 -0.094 -0.100 0.619 1.129 1.291 1.053 1.036
(-0.115,0.018)(-0.132,0.010)(-0.176,-0.011)(-0.079,0.047)(-0.138,-0.033)(-0.170,-0.019)(-0.203,0.015)(0.568,0.668) (1.028,1.237) (1.102,1.535) (0.951,1.164) (0.939,1.138)
PAR 0.022 0.010 -0.023 0.055 -0.015 -0.024 -0.029 0.071 0.548 1.144∗ 0.933∗ 0.917
(-0.034,0.078)(-0.053,0.073) (-0.092,0.047) (0.004,0.105) (-0.054,0.024) (-0.093,0.045) (-0.125,0.078)(0.016,0.125) (0.511,0.583) (0.986,1.352) (0.856,1.019)(0.843,0.998)
REB 0.091 0.080∗ 0.045∗ 0.123 0.054∗ 0.045∗ 0.040∗ 0.140 0.069∗ 0.479 0.816 0.802
(0.008,0.174)(-0.007,0.162) (-0.050,0.143) (0.043,0.204) (-0.019,0.125) (-0.049,0.139) (-0.077,0.166)(0.055,0.223) (-0.008,0.146) (0.408,0.549) (0.689,0.948)(0.680,0.930)
SER -0.018 -0.029 −0.063∗ 0.015 -0.055 −0.063∗ -0.069 0.031 −0.040∗ -0.108 0.588 0.983
(-0.075,0.040)(-0.095,0.035) (-0.139,0.017) (-0.039,0.070)(-0.099,-0.010) (-0.135,0.009) (-0.169,0.043)(-0.030,0.092) (-0.089,0.010) (-0.187,-0.029)(0.543,0.629) (0.902,1.071)
VEN -0.028 -0.039 −0.073∗ 0.005 -0.065 -0.073 -0.079 0.021 -0.050 -0.118 -0.010 0.598
(-0.083,0.030)(-0.105,0.025) (-0.149,0.005) (-0.049,0.059)(-0.105,-0.024)(-0.146,-0.000)(-0.177,0.032)(-0.038,0.079)(-0.098,-0.001)(-0.196,-0.040)(-0.061,0.041) (0.555,0.637)
Drugs are reported in alphabetical order. Diagonal panels are the population averaged response rates (i.e., proportion of patients
who had at least 50% reduction from the baseline score on HDRS); upper triangular and lower triangular panels are the relative
risks (RRs) and risk differences (RDs) of the first drug in alphabetical order compared with the second drug in alphabetical
order, respectively. Drugs with higher response rate are more effective; RRs larger than 1.0 or positive RDs favor the first drug in
alphabetical order. To obtain comparisons in the opposite direction, reciprocals should be taken for RR and opposite sign should
be used for RD. Statistically significant results are in bold and underlined. Comparisons statistically significant here but not in
Cipriani et al.[34] or vice versa are noted with *. For all summaries, we report both the Bayesian posterior medians and the 95%
credible intervals. BUR=bupropion, CIT=citalopram, DUL=duloxetine, ESC=escitalopram, FLU=fluoxetine, FVX=fluvoxamine
(FVX), MIL=milnacipran, MIR=mirtazapine, PAR=paroxetine, REB=reboxetine, SER=sertraline, and VEN=venlafaxine.
18
Table 2.5: Population averaged dropout rates (proportions), relative risks, and risk differences of the 12 antidepressantss
BUP CIT DUL ESC FLU FVX MIL MIR PAR REB SER VEN
BUP 0.252 1.202 0.921 1.200 0.982 0.879 0.874 1.002 0.951 0.869∗ 1.170 0.957
(0.210,0.295) (0.925,1.539) (0.695,1.221) (0.940,1.521) (0.813,1.170) (0.654,1.170) (0.646,1.220) (0.783,1.278) (0.777,1.150) (0.653,1.168) (0.938,1.453) (0.785,1.157)
CIT 0.042 0.209 0.768 1.000 0.817 0.732 0.728 0.834 0.790∗ 0.725 0.974 0.795
(-0.018,0.098) (0.173,0.257) (0.575,1.032) (0.783,1.267) (0.663,1.008) (0.544,0.985)(0.530,1.038) (0.648,1.086)(0.638,0.986)(0.542,0.978) (0.777,1.232) (0.635,1.005)
DUL -0.021 -0.063 0.273 1.303∗ 1.065 0.954 0.950 1.088 1.031 0.943 1.270∗ 1.039
(-0.100,0.050) (-0.140,0.007) (0.216,0.343) (0.990,1.693) (0.831,1.350) (0.684,1.318) (0.671,1.372) (0.813,1.445) (0.812,1.299) (0.679,1.315) (0.968,1.656) (0.796,1.343)
ESC 0.042 0.000 0.063∗ 0.209 0.817 0.732 0.730 0.834 0.790 0.725 0.974 0.797
(-0.015,0.096) (-0.052,0.051) (-0.002,0.134) (0.174,0.256) (0.669,1.004) (0.544,0.990)(0.533,1.031) (0.649,1.088)(0.645,0.982)(0.541,0.988) (0.779,1.231) (0.642,0.996)
FLU -0.005 -0.047 0.017 -0.047 0.257 0.896 0.890 1.021 0.968 0.885∗ 1.192∗ 0.975
(-0.050,0.042) (-0.091,0.002) (-0.045,0.087) (-0.089,0.001) (0.232,0.283) (0.699,1.147) (0.687,1.206) (0.844,1.248) (0.855,1.098) (0.698,1.149) (1.017,1.411) (0.851,1.120)
FVX -0.035 -0.077 -0.013 -0.077 -0.030 0.286 0.997 1.140 1.081 0.990 1.332 1.089
(-0.121,0.040)(-0.160,-0.003)(-0.109,0.077)(-0.161,-0.002)(-0.109,0.034) (0.225,0.366) (0.708,1.432) (0.859,1.524) (0.841,1.395) (0.712,1.391) (1.014,1.755) (0.835,1.418)
MIL -0.036 -0.078 -0.014 -0.078 -0.032 -0.001 0.289 1.146 1.087 0.994 1.338 1.095
(-0.127,0.049) (-0.169,0.009) (-0.116,0.085) (-0.168,0.007) (-0.115,0.044) (-0.102,0.101) (0.212,0.372) (0.815,1.568) (0.800,1.424) (0.684,1.419) (0.966,1.793) (0.793,1.452)
MIR 0.001 -0.042 0.022 -0.042 0.005 0.035 0.037 0.252 0.949 0.867 1.168 0.955
(-0.062,0.061) (-0.101,0.019) (-0.052,0.101) (-0.101,0.019) (-0.046,0.053) (-0.039,0.120)(-0.051,0.130)(0.208,0.301) (0.774,1.155) (0.647,1.175) (0.929,1.463) (0.770,1.177)
PAR -0.013 -0.055∗ 0.008 -0.055 -0.008 0.021 0.023 -0.014 0.265 0.915 1.231 1.007
(-0.063,0.037)(-0.102,-0.004)(-0.052,0.077)(-0.100,-0.005)(-0.042,0.024) (-0.044,0.101)(-0.054,0.108)(-0.063,0.039) (0.235,0.298) (0.709,1.201) (1.035,1.473) (0.855,1.185)
REB −0.038∗ -0.080 -0.016 -0.080 −0.033∗ -0.003 -0.002 -0.038 -0.025 0.290 1.346 1.101
(-0.122,0.039)(-0.161,-0.005)(-0.110,0.077)(-0.162,-0.003)(-0.109,0.034) (-0.099,0.096)(-0.107,0.103)(-0.124,0.042)(-0.104,0.046) (0.225,0.366) (1.014,1.764) (0.835,1.430)
SER 0.037 -0.006 0.058∗ -0.005 0.041∗ 0.071 0.073 0.036 0.050 0.074 0.215 0.818∗
(-0.014,0.089) (-0.052,0.046) (-0.007,0.132) (-0.052,0.046) (0.004,0.078)(0.003,0.153)(-0.008,0.160)(-0.016,0.092)(0.008,0.091)(0.003,0.154) (0.184,0.249) (0.677,0.984)
VEN -0.011 -0.054 0.010 -0.053 -0.007 0.023 0.025 -0.012 0.002 0.026 -0.048∗ 0.263
(-0.061,0.038) (-0.105,0.001) (-0.057,0.085)(-0.102,-0.001)(-0.043,0.029) (-0.046,0.105)(-0.057,0.113)(-0.065,0.044)(-0.042,0.044) (-0.046,0.107)(-0.093,-0.004) (0.230,0.301)
Drugs are reported in alphabetical order. Diagonal panels are the population averaged dropout rate, upper triangular
and lower triangular panels are the relative risks (RRs) and risk differences (RDs) of the first drug in alphabetical or-
der compared with the second drug in alphabetical order, respectively. Drugs with lower dropout rate are more ac-
ceptable; RRs smaller than 1.0 or negative RDs favor the first drug in alphabetical order. To obtain comparisons in
the opposite direction, reciprocals should be taken for RR and opposite sign should be used for RD. Statistically signifi-
cant results are in bold and underlined. Comparisons statistically significant here but not in Cipriani et al[34]. or vice
versa are noted with *. For all summaries, we report both the Bayesian posterior medians and the 95% credible inter-
vals. BUR=bupropion, CIT=citalopram, DUL=duloxetine, ESC=escitalopram, FLU=fluoxetine, FVX=fluvoxamine (FVX),
MIL=milnacipran, MIR=mirtazapine, PAR=paroxetine, REB=reboxetine, SER=sertraline, and VEN=venlafaxine.
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ESC and sertraline (SER) were more effective and more acceptable as measured
by the proportion responding and discontinuing treatment. MIR and VEN had good
efficacy but low acceptability as measured by the proportion discontinuing treatment.
CIT had high acceptability but low efficacy. To visually compare the efficacy and
acceptability of the 12 antidepressant drugs, Figure 2.1 presents the treatment-specific
posterior medians of response and dropout proportions, with their 95% posterior credible
intervals.
As compared to the results of Cipriani et al. [34], for efficacy, we did not find
significant differences between SER and DUL, FVX, and PAR, nor between VEN and
DUL. REB was only less effective than BUP, ESC, MIR, SER, and VEN, but not other
treatments. In terms of acceptability, both ESC and SER are better-tolerated than
FVX, PAR, REB, and VEN. In addition, SER is better-tolerated than FLU. CIT is
better-tolerated than not only FVX and REB, but also PAR. Lastly, we did not find
significant differences comparing BUP versus REB, and DUL versus ESC and SER.
Figure 2.2 compares the ORs reported in Cipriani et al. [34] (y-axis) against the
RRs estimated from our model (x-axis) of the 66 head-to-head comparisons of efficacy
and treatment discontinuation. As expected, given how common the outcomes are,
81.1% (107/132) of the treatment effects are overestimated using the OR instead of
the RR; only 18.9% (25/132) were underestimated. For efficacy, the overestimation can
be as high as 57.4% (OR = 2.03 vs. RR = 1.29 comparing MIR vs. REB) while the
underestimation is as high as 5.3% (OR = 1.00 vs. RR = 0.95 comparing MIL and
PAR); for acceptability, the overestimation goes up to 28.7% (OR = 0.62 vs. RR =
0.87 comparing BUP vs. REB) while the underestimation can be as large as 19.2% (OR
= 0.87 vs. RR = 0.73 comparing CIT and MIL). In addition, 7.6% (10/132) of the
comparisons between ORs and RRs have opposite signs, for which both estimates are
very close to the null (see red symbols in Figure 2). A direct comparison between the
reported ORs in Cipriani et al6 and our marginal ORs is presented in the web appendix,
and similar conclusions are shown.
Comparative efficacy and acceptability of antimanic drugs in acute mania
Cipriani et al. [35] comprehensively reviewed 68 randomized controlled trials (16,073
participants) from Jan 1, 1980 to Nov 25, 2010, which compared antimanic drugs at
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Figure 2.1: Response and dropout rates of the 12 antidepressants
therapeutic dose range for the treatment of acute mania in adults. The main outcomes
were the mean change on mania rating scales and the proportion of patients who dis-
continued the assigned treatment at 3 weeks (dichotomous outcome for acceptability).
The secondary outcome was response rate (response rate was defined as the proportion
of the total number of patients who had a reduction of at least 50% on the total score
between baseline and endpoint on a standardized rating scale for mania). Here, we only
focus on the binary response for efficacy and the treatment discontinuation or dropout
rate. Two treatments, gabapentin and asenapine that were only included in one or two
trials were excluded.
Table 6 summarizes the efficacy results. The population-averaged treatment-specific
response rates ranged from 0.22 (95% CI 0.08 to 0.48) for topiramate (TOP) to 0.56
for olanzapine (OLA) (95% CI 0.49 to 0.63) and haloperidol (HAL) (95% CI 0.48 to
0.64). Compared to placebo, RRs and RDs are significant for all antimanic treatments,
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Figure 2.2: Comparison of the ORs versus the RRs for the 12 antidepressants
except lamotrigine (LAM) and TOP. In addition, all active treatments except LAM
and ziprasidone (ZIP) are significantly more effective than TOP. Table 7 shows the
results for acceptability (dropout). The population-averaged treatment-specific dropout
proportions range from 0.30 for risperidone (RIS) (95% CI 0.24 to 0.37) and OLA (95%
CI 0.25 to 0.36) to TOP at 0.48 (95% CI 0.32 to 0.65). The upper and lower triangular
panels report the RRs and RDs of all pairwise comparisons.
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Table 2.6: Population-averaged responses rates (proportions), relative risks, and risk differences of the 12 Antimanic
drugs
ARI CAR HAL LAM LIT OLA PLA QUE RIS TOP VAL ZIP
ARI 0.504 0.956 0.903∗ 0.949 0.918 0.897 1.369 0.925 0.917 2.332 0.955 1.055
(0.437,0.574) (0.720,1.374) (0.750,1.081) (0.607,2.242) (0.749,1.126) (0.749,1.074) (1.167,1.586) (0.766,1.117) (0.758,1.106) (1.046,6.538) (0.780,1.169) (0.858,1.326)
CAR -0.023 0.528 0.944∗ 0.994 0.959 0.939 1.433 0.967 0.959 2.427 0.998 1.105
(-0.183,0.145) (0.376,0.675) (0.658,1.258) (0.577,2.381) (0.666,1.295) (0.658,1.240) (1.006,1.863) (0.677,1.286) (0.667,1.274) (1.034,6.899) (0.695,1.342) (0.763,1.507)
HAL −0.054∗ −0.031∗ 0.559 1.053∗ 1.017∗ 0.995 1.517 1.026∗ 1.017 2.587 1.059∗ 1.171∗
(-0.153,0.041) (-0.202,0.134) (0.482,0.637) (0.670,2.486) (0.824,1.254) (0.832,1.183) (1.289,1.767) (0.845,1.239) (0.840,1.221) (1.156,7.262) (0.861,1.299) (0.950,1.456)
LAM -0.027 -0.003 0.028∗ 0.531 0.964 0.944∗ 1.440 0.974 0.965∗ 2.405 1.004 1.110
(-0.314,0.285) (-0.321,0.334) (-0.262,0.341) (0.226,0.810) (0.409,1.526) (0.401,1.478) (0.612,2.236) (0.412,1.528) (0.408,1.516) (0.762,7.371) (0.424,1.589) (0.469,1.778)
LIT -0.045 -0.023 0.009∗ -0.020 0.550 0.978 1.491 1.007 1.000 2.544 1.041 1.149
(-0.154,0.061) (-0.196,0.148) (-0.108,0.123)(-0.334,0.274) (0.463,0.639) (0.804,1.185) (1.239,1.778) (0.825,1.239) (0.806,1.233) (1.131,7.142) (0.838,1.288) (0.918,1.468)
OLA -0.058 -0.034 -0.003 −0.031∗ -0.012 0.563 1.524 1.031 1.022 2.598 1.065∗ 1.177∗
(-0.152,0.038) (-0.200,0.127) (-0.101,0.094)(-0.343,0.258)(-0.117,0.096) (0.490,0.630) (1.325,1.753) (0.861,1.240) (0.855,1.221) (1.165,7.300) (0.889,1.275) (0.963,1.464)
PLA 0.136 0.160 0.190 0.162 0.181 0.194 0.368 0.676 0.669 1.702 0.698 0.771
(0.064,0.207)(0.002,0.308)(0.111,0.270)(-0.144,0.445)(0.091,0.274)(0.124,0.264) (0.331,0.409) (0.578,0.798)(0.573,0.789) (0.772,4.795) (0.589,0.832)(0.650,0.936)
QUE -0.041 -0.018 0.014∗ -0.014 0.004 0.017 -0.177 0.546 0.991 2.527 1.033 1.142
(-0.140,0.057) (-0.184,0.146) (-0.092,0.117)(-0.328,0.275)(-0.103,0.119) (-0.083,0.117) (-0.256,-0.097) (0.470,0.620) (0.820,1.201) (1.129,7.062) (0.837,1.266) (0.926,1.429)
RIS -0.046 -0.023 0.009 −0.019∗ -0.000 0.012 -0.182 -0.005 0.550 2.547 1.042∗ 1.151∗
(-0.146,0.052) (-0.192,0.140) (-0.096,0.110)(-0.333,0.271)(-0.116,0.116) (-0.087,0.109) (-0.261,-0.103) (-0.108,0.099) (0.475,0.628) (1.135,7.163) (0.847,1.279) (0.934,1.441)
TOP 0.287 0.306 0.341 0.305 0.332 0.344 0.151 0.328 0.332 0.216 0.409 0.453∗
(0.022,0.445)(0.015,0.514)(0.073,0.506)(-0.087,0.630)(0.061,0.501)(0.078,0.504) (-0.108,0.300) (0.060,0.488)(0.064,0.496) (0.078,0.478) (0.146,0.912) (0.161,1.020)
VAL -0.024 -0.001 0.031∗ 0.002 0.022 0.034∗ -0.159 0.018 0.022∗ -0.310 0.528 1.106
(-0.131,0.079) (-0.172,0.166) (-0.082,0.140)(-0.314,0.294)(-0.094,0.137) (-0.065,0.129)(-0.247,-0.077)(-0.096,0.125) (-0.090,0.131)(-0.477,-0.045) (0.449,0.615) (0.885,1.403)
ZIP 0.026 0.050 0.082∗ 0.053 0.071 0.085∗ -0.109 0.068 0.072∗ −0.260∗ 0.050 0.479
(-0.076,0.134) (-0.121,0.218) (-0.027,0.189)(-0.262,0.346)(-0.044,0.195) (-0.020,0.189)(-0.191,-0.026)(-0.040,0.176) (-0.035,0.182) (-0.424,0.009) (-0.061,0.167) (0.394,0.557)
Drugs are reported in alphabetical order. Diagonal panels are the population-averaged response rate; upper triangular and lower
triangular panels are the relative risks (RRs) and risk differences (RDs) of the first drug in alphabetical order compared with the
second drug in alphabetical order, respectively. Drugs with higher response rate are more effective; RRs larger than 1.0 or positive
RDs favor the first drug in alphabetical order. To obtain comparisons in the opposite direction, reciprocals should be taken for
RR and opposite sign should be used for RD. Statistically significant results are in bold and underlined. Comparisons statistically
significant here but not in Cipriani et al[35]. or vice versa are noted with *. For all summaries, we report both the Bayesian pos-
terior medians and the 95% credible intervals. ARI=aripiprazole, CAR=carbamazepine, HAL=haloperidol, LAM=lamotrigine,
LIT=lithium, OLA=olanzapine, PLA=placebo, QUE=quetiapine, RIS=risperidone, TOP=topiramate, VAL=valproate, and
ZIP=ziprasidone.
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Table 2.7: Population-averaged dropout rates (proportions), relative risks, and risk differences of the 12 Antimanic
drugs
ARI CAR HAL LAM LIT OLA PLA QUE RIS TOP VAL ZIP
ARI 0.368 1.013 0.960 0.884 1.012 1.219 0.902 1.152 1.224 0.761∗ 1.067 0.911
(0.295,0.443) (0.714,1.507) (0.746,1.254) (0.617,1.341) (0.786,1.304) (0.950,1.564) (0.737,1.078) (0.813,1.687) (0.928,1.613) (0.538,1.177) (0.807,1.416) (0.702,1.176)
CAR 0.005 0.363 0.949 0.870 0.997 1.202 0.889 1.132 1.206 0.753∗ 1.051 0.898
(-0.133,0.134) (0.249,0.489) (0.641,1.342) (0.552,1.409) (0.684,1.401) (0.818,1.696) (0.620,1.201) (0.727,1.782) (0.803,1.748) (0.476,1.222) (0.707,1.513) (0.603,1.272)
HAL -0.015 -0.020 0.381 0.918 1.050 1.267∗ 0.934 1.192 1.269 0.792∗ 1.108 0.945
(-0.111,0.084)(-0.149,0.118) (0.307,0.469) (0.638,1.404) (0.812,1.371) (0.998,1.616) (0.767,1.139) (0.856,1.774) (0.978,1.677) (0.557,1.225) (0.843,1.473) (0.733,1.228)
LAM -0.048 -0.054 -0.034 0.416 1.145 1.382∗ 1.020 1.302 1.384∗ 0.864 1.207 1.030
(-0.207,0.102)(-0.231,0.128)(-0.195,0.121) (0.284,0.564) (0.765,1.620) (0.912,1.958) (0.695,1.386) (0.817,2.041) (0.908,2.001) (0.537,1.396) (0.786,1.757) (0.680,1.471)
LIT 0.004 -0.001 0.018 0.052 0.363 1.207∗ 0.891 1.140∗ 1.211∗ 0.754 1.054 0.900
(-0.086,0.097)(-0.122,0.134)(-0.076,0.120)(-0.092,0.207) (0.296,0.437) (0.939,1.532) (0.729,1.065) (0.811,1.639) (0.916,1.589) (0.532,1.146) (0.801,1.387) (0.699,1.159)
OLA 0.066 0.061 0.080∗ 0.115∗ 0.062∗ 0.301 0.739 0.943 1.003 0.624 0.875 0.746∗
(-0.017,0.151)(-0.058,0.194)(-0.001,0.169)(-0.028,0.267)(-0.020,0.143) (0.245,0.363) (0.621,0.869) (0.681,1.366) (0.780,1.303) (0.447,0.959) (0.688,1.113) (0.586,0.955)
PLA -0.040 -0.045 -0.027 0.008 -0.044 -0.106 0.408 1.277∗ 1.359 0.844 1.183 1.010
(-0.109,0.031)(-0.156,0.080)(-0.097,0.056)(-0.127,0.155)(-0.114,0.026)(-0.157,-0.053) (0.364,0.452) (0.970,1.785) (1.113,1.680) (0.632,1.256) (0.974,1.470) (0.850,1.221)
QUE 0.048 0.042 0.061 0.096 0.045∗ -0.018 0.088∗ 0.318 1.064 0.662∗ 0.927 0.790
(-0.076,0.165)(-0.105,0.197)(-0.058,0.187)(-0.070,0.268)(-0.078,0.154) (-0.132,0.087) (-0.013,0.181) (0.226,0.433) (0.733,1.477) (0.434,1.056) (0.626,1.321) (0.541,1.109)
RIS 0.067 0.062 0.081 0.115∗ 0.063∗ 0.001 0.107 0.019 0.300 0.621 0.872 0.743∗
(-0.025,0.158)(-0.065,0.201)(-0.007,0.178)(-0.030,0.271)(-0.029,0.152) (-0.077,0.078) (0.041,0.168)(-0.088,0.131) (0.238,0.374) (0.436,0.968) (0.655,1.164) (0.566,0.977)
TOP −0.115∗ −0.119∗ −0.100∗ -0.065 -0.118 -0.181 -0.075 −0.162∗ -0.182 0.482 1.401∗ 1.193
(-0.291,0.060)(-0.316,0.078)(-0.279,0.077)(-0.278,0.142)(-0.296,0.049)(-0.352,-0.014) (-0.238,0.084) (-0.342,0.020)(-0.355,-0.011) (0.324,0.654) (0.898,2.010) (0.778,1.696)
VAL 0.023 0.018 0.037 0.071 0.019 -0.043 0.063 -0.025 -0.044 0.138∗ 0.345 0.854
(-0.077,0.121)(-0.110,0.156)(-0.062,0.140)(-0.081,0.231)(-0.080,0.112) (-0.125,0.033) (-0.011,0.131) (-0.145,0.098) (-0.138,0.048) (-0.038,0.314) (0.269,0.426) (0.645,1.116)
ZIP -0.036 -0.041 -0.022 0.012 -0.041 -0.102∗ 0.004 -0.084 -0.103∗ 0.078 -0.059 0.404
(-0.134,0.062)(-0.172,0.100)(-0.119,0.082)(-0.139,0.173)(-0.137,0.056)(-0.188,-0.016) (-0.070,0.076) (-0.201,0.040)(-0.197,-0.008) (-0.096,0.260) (-0.158,0.042) (0.331,0.480)
Drugs are reported in alphabetical order. Diagonal panels are the population-averaged dropout rate; upper triangular and lower
triangular panels are the relative risks (RRs) and risk differences (RDs) of the first drug in alphabetical order compared with the
second drug in alphabetical order, respectively. Drugs with lower dropout rate are more acceptable; RRs lower than 1.0 or nega-
tive RDs favor the first drug in alphabetical order. To obtain comparisons in the opposite direction, reciprocals should be taken for
RR and opposite sign should be used for RD. Statistically significant results are in bold and underlined. Comparisons statistically
significant here but not in Cipriani et al.[35]. or vice versa are noted with *. For all summaries, we report both the Bayesian pos-
terior medians and the 95% credible intervals. ARI=aripiprazole, CAR=carbamazepine, HAL=haloperidol, LAM=lamotrigine,
LIT=lithium, OLA=olanzapine, PLA=placebo, QUE=quetiapine, RIS=risperidone, TOP=topiramate, VAL=valproate, and
ZIP=ziprasidone.
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To visually compare the efficacy and acceptability of the 12 antimanic drugs, Fig-
ure 2.3 plots the treatment-specific posterior medians of the response and dropout pro-
portions, with their 95% posterior credible intervals. The 95% credible intervals of LAM
and TOP are extremely wide because they are studied in only 3 and 5 trials respectively,
much fewer than the others. TOP is less effective and less well tolerated than placebo.
Our results differ from Cipriani et al. [35] in some aspects. For efficacy, we do
not find significant differences between HAL, RIS, and OLA with the other treatments,
while in Cipriani et als paper.7, HAL, RIS, and OLA showed significant efficacy com-
pared with some other treatments. For acceptability, except that OLA and RIS have
significantly lower proportions of discontinuation compared to placebo, TOP, and ZIP,
we do not find any other statistically significant head-to-head comparisons. In contrast,
Cipriani et al. [35] found that OLA, RIS, and quetiapine (QUE) led to significantly
fewer discontinuations than did lithium (LIT), LAM, placebo, and TOP.
Figure 2.4 compares the ORs reported in Cipriani et al. [35] (y-axis) against the RRs
estimated from our model (x-axis) of the 66 head-to-head comparisons for treatment
discontinuation (acceptability) and the 11 comparisons with placebo for efficacy. Over-
all, 90.9% (70/77) of the treatment effects are overestimated, and 9.1% (7/77) of them
are underestimated. Specifically, for efficacy, the overestimation is as high as 74.8% (OR
= 1/0.40 = 2.50 vs. RR = 1.43 comparing CAR vs. placebo) while the underestimation
is as high as 30.5% (OR = 1/1.30 = 0.77 vs. RR =1/1.70 = 0.59 comparing TOP and
placebo). For acceptability, the overestimation is as large as 54.3% (OR = 1/0.47 =
2.13 vs. RR = 1.38 comparing LAM vs. OLA), while the underestimation is as large as
18.0% (OR=1.05 vs. RR=0.89 comparing LIT and placebo). In addition, 6.1% (4/66)
of the comparisons between the RRs and the ORs for acceptability are in the opposite
direction of the null (red plotting symbols in Figure 4). A direct comparison between
the reported ORs in Cipriani et al. [34] and our marginal ORs is presented in the web
appendix, and similar conclusions are shown.
2.4 Discussion
Network meta-analysis is increasingly utilized to synthesize direct and indirect evi-
dence for different treatments. However, many current network meta-analyses focus on
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Figure 2.3: Response and dropout rates of the 12 antimanic drugs
treatment contrasts, in which one of the arms of each study is chosen as ”baseline”.
Since different studies may have different ”baselines”, as a consequence of changing
standards of care or changes in the underlying risks of study populations (e.g., ini-
tial trial may include more severely ill patients), specifying a common distribution for
baseline groups is generally not interpretable. Although one may prefer to leave the
baseline treatment as a fixed, study-specific parameter with the argument that they
are fundamentally different from each other. However, while we make a relatively
strong assumption on exchangeability of the probability of events within each treat-
ment group across studies, our model is valid under the missing at random (MAR)
assumption. The contrast-based Lu and Ades approach is valid only under a miss-
ing completely at random (MCAR) assumption, as shown in a recent AHRQ report
(http://www.ncbi.nlm.nih.gov/books/NBK116689/pdf/TOC.pdf) and a corresponding
technical report [78]. In addition, many current NMA methods only report the relative
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Figure 2.4: Comparison of the ORs versus the RRs for the 12 antimanic drugs
treatment effect on an OR scale [47][48][49][16][17][79][80][55]. Although they do offer
valid statistical significance testing concerning the OR and can incorporate data from
studies that only report relative treatment effects, without making strong assumptions
on the event rate in a reference group, they fail to report treatment-specific event rates,
risk differences and relative risks, which should be considered in making treatment rec-
ommendations. Although in some cases, it is unfortunate that some people tend to
misspecify the distribution for the reference group and sometimes can lead to incorrect
inference and interpretation, it should not construed to against our effort to estimate
and report treatment-specific event rates. With the two comprehensive overviews, we
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illustrate how this novel arm-based Bayesian hierarchical model can be used to estimate
these key statistics, and in some circumstances lead to different conclusions.
For the two NMAs [34][35] considered, relatively high response proportions (up to
0.62) were observed. The differences between ORs and RRs that we illustrate can be
explained in large part by the theoretical difference between the OR and the RR for
common events [81]. The limitation of only reporting the ORs is discussed in detail in
the web appendix. There is also a theoretical difference between the marginal treatment
effects averaged over all studies by our approach, and the conditional treatment effects
reported for a typical NMA by the contrast-based approaches such as used by Cipriani
et al. [34][35]. Marginal treatment effects are generally smaller than the conditional
treatment effects estimated from random effects models [82]. Finally, our differing
ORs and RRs may partially be the result of the potential difference between model
assumptions (e.g., the assumed variance and correlation structure) and the potential
bias using current contrast-based models as illustrated in the hypothetical data analyses.
To compare the performance of the proposed arm-based versus current contrast-
based Bayesian hierarchical models, we create two hypothetical network meta-analysis
data sets including 11 trials and 3 treatment arms under either a homogenous RR
or a homogenous RD assumption, in which the full data sets (i.e., assuming each trial
compares all treatment arms) are available to estimate the true parameters (see details in
the Web appendix). We found that the proposed arm-based NMA method outperformed
the current contrast-based NMA methods.
In addition to some common concerns of network meta-analysis [83][38][67], there are
some additional limitations for the proposed network meta-analysis approaches. First,
to facilitate the estimation of treatment-specific population-averaged event proportions,
we assume that each study hypothetically compares all treatments, with unstudied arms
being missing at random conditional on the observed arms. Such models allow us to
borrow information across multiple treatments within studies to reduce potential bias.
However, it is plausible that investigators may have selected treatment arms on pur-
pose based on the results of previous trials, which may lead to nonignorable missingness
and potentially bias our event rate estimation. In addition, to robustly estimate event
rates for each treatment, it is very important to have adequate number of trials with
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adequate samples for each treatment in a network meta-analysis. Different model as-
sumptions may lead to different results in poorly connected networks. Second, in this
article, we only considered a saturated multivariate Bayesian hierarchical mixed model
with unstructured variance-covariance matrix. Although various model simplifications
gave similar results (not presented), we did not perform analysis over all possible re-
duced models (e.g. models with equal variances, and/or equal correlations among all
treatments), a number of which may further improve statistical efficiency. Arguably,
the unstructured variance-covariance matrix allows us to better summarize the evidence
contained in the data without enforcing an artificial structure, such as equal variances
or equal correlations. Third, in addition to the evaluation of heterogeneity of treatment
effects, inconsistency is a major concern in network meta-analysis. Much ongoing de-
bate over the value of network meta-analysis concerns the agreement between the direct
and indirect evidence. In addition, inconsistency and its trade-off with heterogeneity
can be very important when selecting the scale for NMA [83]. Achana et al.[84] has pro-
posed an important method to adjust for baseline imbalance in order to possibly reduce
heterogeneity and inconsistency for the CB methods. Some statistical methods have
been proposed for identifying this disagreement when using contrast-based approaches
with the odds ratio as the main effect measure [17][27][85][26][86], statistical methods
for identifying and accounting for potential inconsistency based on our proposed mod-
els, formulated from the missing data perspective, await further development. Finally,
in this paper, we do not consider individual-level or study-level covariates, which has
already been briefly discussed elsewhere [87][88].
In summary, we have proposed and implemented a novel arm-based multiple-treatments
meta-analysis in a Bayesian framework, which is different than the methods used by
Cipriani in two NMAs [34][35]. With this arm-based approach, estimates of treatment-
specific event rates or proportions, RDs and RRs are provided. Using two hypothetical
data sets, we show that our method provides more accurate estimates than the meth-
ods used by Cipriani et al. [34][35]. Such differences could lead to different treatment
recommendations.
Chapter 3
Bayesian hierarchical models for
network meta-analysis
incorporating nonignorable
missingness
In this chapter, we extend the missing at random (MAR) model proposed in Chapter
2 to incorporate nonignorable missingness using selection models approach. Section 3.1
introduces the proposed method which jointly models the observed data and missingness
indicator. We also show various important model simplifications. In Section 3.2, we
apply our proposed model to a smoking cessation data set, and compare the results
with those obtained from models assuming ignorable missingness. We then conduct
various simulation studies in Section 3.3 to investigate the performance of our proposed
method in handling the nonignorable missingness. We also compare comprehensively
the performance of the AB method and the CB method using extensive simulation
studies in this section. Finally, Section 3.4 summarizes our findings and conclusions.
29
30
3.1 Statistical methods
Nonignorable missingness (or MNAR) is inevitable when selectively choosing treatments
to include in trials or selectively choosing trials to include in an NMA. Unfortunately, one
can never tell from the data at hand whether the missing values are MAR or MNAR
[59]. The fundamental difficulty is that potential “lurking variables” controlling the
missingness are unobserved—by definition—and so we can never rule them out. Rather
than trying to test whether the missing values are MAR, we develop a sensitivity analysis
tool to explore how inferences may change if the assumption of MAR is violated. Note
that even if an assumption of MAR seems reasonable, it is worthwhile to investigate
how the results may change under nonignorable missingness.
We now introduce a partition of the complete data Y into observed values, Yobs,
and missing values, Ymis, i.e., Y = (Yobs, Ymis). Let R be a I × K indicator matrix
for missingness in a NMA containing I trials and K treatments. Then (Yobs, Ymis, R)
and (Yobs, R) are referred to as the complete data and observed data, respectively. The
practical implication of MNAR is that the likelihood requires an explicit model for R.
Selection models, which were introduced by the econometrician Heckman [89], provide
this explicit form. They factor the joint distribution of the complete data and the miss-
ingness indicators into a marginal density for the complete data and a conditional den-
sity for the missingness indicators given the complete data, i.e., f(Yobs, Ymis, R|θ, α) =
f(Yobs, Ymis|θ, α)f(R|Yobs, Ymis, θ, α), where θ is the parameter for the complete data and
α is the parameter for the missingness mechanism. This factorization can usually be
simplified to f(Yobs, Ymis, R|θ, α) = f(Yobs, Ymis|θ)f(R|Yobs, Ymis, α), if we assume that
Y |θ is conditionally independent of α, and R|Yobs, Ymis, α is conditionally independent
of θ, which is usually reasonable in practice. We in further call f(Yobs, Ymis|θ) the model
of interest (MOI) and f(R|Yobs, Ymis, α) the model of missingness (MOM) [90].
Consider a collection of RCTs i = 1, 2, . . . , I, each of which only includes a subset
of the complete collection of K treatments. Let ki be the number of treatments, and Si
be the set of treatments that are compared in the ith trial. Trials with ki ≥ 3 are called
“multi-arm” trials, in contrast to ki = 2 for “two-arm” trials. For our binary data, let
Di = (yik, nik), k ∈ Si, i = 1, 2, . . . , I denote the available data from the ith trial, where
nik is the total number of subjects and yik is the total number of responses for the k
th
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arm in the ith trial. The corresponding probability of response is denoted by pik.
For the MOI, we consider the multivariate generalized linear mixed model (MGLMM)
as in Chapter 2. (Yobs, Ymis) can be written as a collection of vectors (y1, . . . , yI) for
I trials, where each vector yi contains two parts, yi,obs and yi,mis. The elements yik
of yi = {yik} are assumed to be independently binomially distributed with probability
pik. A multivariate normal distribution (MVN) for pik on a transformed scale, similar
to that in Chapter 2, is then assumed as follows:
g(pik) = µk + νik, (νi1, . . . , νiK)
T ∼MVN(0,Σk), (3.1)
where g() is some appropriate link function, µk is the fixed effect for the k
th treatment,
νik is the random effect for the k
th treatment in the ith trial, and (νi1, . . . , νiK) is a
vector of random effects whose covariance matrix is Σk. A possible factorization of ΣK
is ΣK = diag(σ1, . . . , σK) × ΩK × diag(σ1, . . . , σK), where ΩK is a positive definite
correlation matrix with off-diagonal elements ρk1k2 , σk is the standard deviation for
random effect νik, and diag(σ1, . . . , σK) is a diagonal matrix with elements σi. In
(3.1), the trial-level heterogeneity in response to treatment k is captured by σk, and the
within-trial dependence among treatments is captured by ΩK . An advantage of our AB
method over the CB method is that the population-averaged event rate can then be
calculated, for example with the probit link, in a closed form as pik = E(pik|µk, σk) =∫∞
−∞Φ(µk + σkz)φ(z)dz = Φ(µk/
√
1 + σ2k), k = 1, . . . ,K, where Φ() is the standard
normal cumulative density function and φ() is the standard normal density function.
As such, marginal measures may be calculated as RRkl = pik/pil, RDkl = pik − pil, and
ORkl =
pik/(1−pik)
pil/(1−pil) . We can also use an other link function, for example logit link, under
which condition, the population-averaged event rate is pik ≈ expit(µk/
√
1 + C2σ2k),
where C = 16
√
3/(15pi) and expit(x) = ex/(1 + ex) [82].
For the MOM, let Rik be an element of the matrix R = (Rik), taking values Rik =
0 if yik is observed and Rik = 1 if yik is missing. If f(R|Yobs, Ymis, α) = f(R|α),
the mechanism is MCAR; if f(R|Yobs, Ymis, α) = f(R|Yobs, α), it is MAR; if there is
no simplification for the conditional distribution f(R|Yobs, Ymis, α), it is MNAR. We
assume Rik has a Bernoulli distribution with a probability of missingness p
mis
ik , i.e.,
Rik ∼ Ber(pmisik ), where pmisik may well depends on yik. A common way to realize the
above is through linking pmisik with the estimated pik (which is an approximation of
yik
nik
)
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instead of yik, i.e., let g(p
mis
ik ) = f(pik), where g(p
mis
ik ) and f(pik) are some prespecified
functions of pmisik and pik.
Finally the joint distribution of Yobs and R can be derived by integrating out the
Ymis as follows
P (Yobs, R) = Π
I
i=1
{∫ {
ΠKk=1(pik)
yik(1− pik)nik−yik ×ΠKk=1(pmisik )Rik(1− pmisik )1−Rik
}
dYmis
}
.
(3.2)
3.1.1 MOIs incorporating heterogeneity
Heterogeneity refers to the between-trial variation, i.e., multiple studies of the same
research question may have different underlying values of the effect measure being esti-
mated. Specifically, heterogeneity may be said to be present for treatment k if pik 6= pjk
for some pair of trials i and j. A common solution to heterogeneity is through a random-
effects model, which assumes that the underlying effects in trials of the same treatment
come from a common distribution, usually normal.
In this paper we use the probit link for all models of interest and talk about various
simplifications of (3.1). The simplest model incorporating heterogeneity can be specified
as Φ−1(pik) = µk + νi (MOI i), where νi ∼ N(0, σ2), corresponding to a covariance
matrix ΣK = σ
2IK . MOI i can be expanded to allow heterogeneous variances σ
2
k
instead of σ2 as Φ−1(pik) = µk + νik with νik ∼ N(0, σ2k). We call this MOI ii. This
special structure allows each treatment group to have its own heterogeneity parameter
σk and a random treatment effect of (σk − σl)ηi comparing treatment k versus l (k 6=
l) in the ith trial where ηi
iid∼ N(0, 1). Another way to expand model MOI i is to
assume Φ−1(pik) = µk + νik, where (νi1, νi2, . . . , νiK) has an exchangeable correlation
matrix with parameter ρ and νik has the same variance σ
2. We call this MOI iii. An
even more general model with exchangeable correlations is Φ−1(pik) = µk + νik where
(νi1, νi2, . . . , νiK) has an exchangeable correlation matrix with parameter ρ but different
variances σ2k for different treatment k. We call this MOI iv. The most general model has
an unstructured covariance matrix ΣK , which is an arbitrary K ×K positive definite
covariance matrix; this is model MOI v. This model assumes that the variances of
different treatments are different, and correlations between different pairs of treatments
are also different.
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In general, MOI i is simple but may not be practical in most cases, and there may not
be enough information contained in the data to accurately estimate all the parameters
in MOI v when the number of treatments K is large and the number of studies I is
small. Thus the exchangeable correlation models MOI iii and MOI iv appear to offer
sensible yet practical alternatives.
3.1.2 MOM specification
Turning to the problem of specifying the model of missingness (MOM), we use the
formula logit(pmisik ) = α0k + α1k × logit(pik) (denoted MOM i) to link the probability
of missingness pmisik to the estimated pik, where α0k is an unknown scalar parameter,
and α1k determines the missing mechanism, i.e., nonignorable missingness if α1k 6= 0
and ignorable missingness if α1k = 0. In this model, the probabilities of missingness for
different treatments have different missingness parameters α1k. A simpler model can be
specified as logit(pmisik ) = α0k + α1 × logit(pik) (denoted MOM ii), where all treatments
share the same missingness parameter α1.
3.1.3 Prior distributions, computation, and model selection
Since improper prior distributions may lead to improper posteriors in some complex
models [69][70][91][92], we select minimally informative but proper priors. Specifically,
we chose a very weakly informative priorN(0, 1000) for µk, and a moderately informative
Gamma(1, 1) prior for the precisions τ = 1/σ2 in MOI i and τi = 1/σ
2
i in MOI ii,
corresponding to a 95% Bayesian CI for variance parameters ranging from 0.27 to 39.5.
In MOI iii and MOI iv, σ and σk have a uniform prior U(0, 5) and ρ has a uniform prior
U(0.0001, 1). A vague Wishart prior is set for the precision matrix in the unstructured
model MOI v, i.e., Σ−1K ∼ W (V, n), where n = K is the degrees of freedom and V is
a known K ×K matrix with diagonal elements equal to 1.0 and off-diagonal elements
equal to 0.005 [8]. It turns out that the above prior corresponds to a 95% Bayesian CI
for the variance parameters ranging from 0.45 to 32.1, and a 95% Bayesian CI for the
correlation parameters ranging from −1.00 to 1.00 (i.e., fully noninformative). Finally
we specify a logistic(0, 1) prior for α0k and a weakly informative N(0, 0.68) prior for α1
and α1k [93][94], which correspond to an approximately flat prior on the scale of p
mis
ik .
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All models were implemented via Markov chain Monte Carlo (MCMC) methods us-
ing the WinBUGS software. We employed a burn-in of 1,000,000 iterations and followed
by 1,000,000 iterations to calculate posterior estimates of the parameters of interest. The
convergence of MCMC chains is assessed by the Gelman-Rubin convergence statistic and
a visual inspection of the chains.
The Deviance Information Criterion (DIC) [95] was used as the model selection
criterion. The deviance, up to an additive quantity not depending upon θ, is D(θ) =
−2logL(θ; Data), where L(θ; Data) is the likelihood for the respective model. The DIC
is given by D(θ) + pD, where D(θ) = Eθ|Data[D(θ)] is the Bayesian deviance, and
pD = D(θ) − D(θ) is the effective number of model parameters. It rewards better
fitting models through the first term and penalizes more complex models through the
second term. A model with smaller overall DIC value is preferred. WinBUGS provides
DIC estimates for the MOIs and MOMs separately, and we call them DIC for model of
Interest (DICI) and DIC for model of Missingness (DICM ) respectively. Ymis are treated
as extra parameters in the MOMs, with the MOI acting as their prior distribution.
Mason et al. [90] have suggested the use of DICM to compare the fit of MOMs with the
same MOI.
3.2 Smoking cessation data application
We apply our Section 2 method to the a smoking cessation data set [96][97] shown in
Table 3.1. This data set comprises 24 trials (22 two-arm and 2 three-arm trials) and
18,822 participants trying to quit smoking using one of the 4 treatments: (A) no contact,
(B) self-help, (C) individual counseling, and (D) group counseling.
Table 3.2 shows the posterior medians of population-averaged event rates (piA, piB,
piC , and piD) and their 95% posterior credible intervals for various models. MOI iii,
MOI iv, and MOI v, which assume random effects (νi1, νi2, . . . , νiK) in the same trial
have a multivariate normal distribution, show smaller DICI than MOI i and MOI ii,
which assume the random effects to be independent. This suggests treatments in the
same trial are correlated. While DICI of MOI iii, MOI iv, and MOI v are quite similar
to each other, we select MOI iii as the best model of interest because it is the simplest
model among these three and is easiest to implement.
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Now let us take a look at the results of a sensitivity analysis. We call the joint
modeling of MOI iii and MOM i “JM i” and the joint modeling of MOI iii and MOM
ii “JM ii”. Table 3.2 shows that the estimates for the population-averaged event rates
piA and piC from JM i and JM ii are exactly the same as MOI iii, while those for piB
and piD are slightly different from MOI iii. This phenomenon suggests that estimates
for treatments A (No Contact) and C (Individual Counseling) are more robust to the
nonignorable missingness, while estimates for B (Self Help) and D (Group Counseling)
are a little more sensitive. However, the differences are quite small, even for the 95%
credible intervals. Note that DICM for “JM i” is smaller than DICM for “JM ii”, thus
MOM i is more suitable for these data than MOM ii. As such, we adopt “JM i” for all
further analysis.
Since the values of α1k control the degree of departure from MAR missingness, we
envisage further sensitivity analyses in which the changes in the estimated parameters
of interest are studied for different values of the missingness parameters α1k. In other
words, we carry out a sensitivity analysis in which a series of models are run with a
set of fixed values for the α1k. More specifically, we use 15 values uniformly distributed
between -1 and 1, namely -1.00, -0.86, -0.71, -0.57, -0.43, -0.29, -0.14, 0.00, 0.14, 0.29,
0.43, 0.57, 0.71, 0.86, and 1.00 for α1k. Figure 3.1 presents the posterior medians and
their 95% credible intervals for the population-averaged response rates versus different
values of α1k. Note that posterior medians of piA and piC versus α1k in the left part of
Figure 3.1 are horizontal lines, while posterior medians of piB and piD versus α1k in the
right part of Figure 3.1 have slight slopes. Thus the conclusion regarding treatments
B and D is that they are slightly dependent on the missingness parameter α1k, but
treatments A and C are more robust to change here, similar to the conclusion from
Table 3.2. Note that in the smoking cessation data, the numbers of trials that contain
treatments A (19) and C (19) are larger than B (6) and D (6), which probably explains
at least part the reason why treatments B and D are more sensitive to the missingness
mechanism choice.
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Figure 3.1: Population event rate variation with changes in α1k
3.3 Simulations
3.3.1 Simulation setups
We compare the performance of the existing CB method (see details in the next para-
graph) and our AB method under MCAR and MAR mechanisms in Simulation 1, and
investigate the influence of nonignorable missingness to our AB method under MNAR
mechanism in Simulation 2. We simulated 1000 replicate data sets. For each replicate,
an NMA comprising 30 trials and 3 treatments (1, 2, and 3) was generated with 100
patients assigned to each arm in each trial for convenience. The bias of parameter esti-
mates, which is the difference between true value and the mean of 1000 posterior median
estimates, and the empirical mean squared error (MSE) were calculated as measures of
performance.
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The most popular CB method [17][80] uses the following Bayesian hierarchical model,
yik
ind∼ Bin(nik, pik), i = 1, . . . , I, k ∈ Si,
logit(pik) = µi +Xikδibk, δibk
ind∼ N(dbk, σ2bk),
where µi is the specified baseline effect that is commonly regarded as a nuisance pa-
rameter; Xik is the indicator for baseline, taking value 0 when k = b and 1 when k 6= b;
b(i) is the specified baseline treatment in trial i, commonly denoted as b for simplicity
as above; and δibk represents the contrast between treatment k and b for the i
th trial
and is assumed to be a random effect with a normal distribution with mean dbk and
variance σ2bk. This method assumes that dhk = dbk − dbh and Corr(δibh, δibk) = γ(b)hk for
h 6= k 6= b.
Simulation 1 The unstructured heterogeneous-variance model MOI v is used to
generate the complete data set which contains 30 trials and 3 arms. We let the mean
parameters have values µ1 = −1.0, µ2 = −0.5, and µ3 = −0.8, standard deviation
parameters have values σ1 = 0.3, σ2 = 0.4, and σ3 = 0.5, and correlation coefficients
have values ρ12 = 0.4, ρ13 = 0.5, and ρ23 = 0.6. The response rate pik for the i
th trial
and kth treatment can be calculated with the above parameters according to formula
pik = Φ(µk+νik), where (νi1, . . . , νiK)
T ∼ MVN(0,Σk) and Σk is the covariance matrix
determined by ρ = (ρ12, ρ13, ρ23) and σ = (σ1, σ2, σ3). Then the number of binary
responses {yik} are randomly generated by a binomial distribution with n = 100 and
probabilities pik. Note that the above parameters correspond to the true population-
averaged treatment-specific response rates pi1 = 0.17, pi2 = 0.32, and pi3 = 0.24, and
thus the true odds ratios are OR21 = 2.33, OR31 = 1.53, and OR32 = 0.66.
Rik represents the missingness, taking value 1 when the record for the k
th treatment
in the ith trial is missing and 0 when the record is present, and pmisik is the corresponding
probability of missingness. We consider simulated scenarios of missingness mimicking
the characteristics of the real smoking cessation data, where most trials (22 trials) are
two-arm trials and only a few (2 trials) are three-arm trials. Arm 2 which records
treatment 2 is assumed to be completely observed, while Arms 1 and 3 have missing
values. We let nmis = 10, 11, 12, 13, 14 trials be missing for Arm 3, and then an-
other nmis trials be missing for Arm 1 selected from the remaining 30− nmis, ensuring
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each trial contains at least 2 treatments (while 30 − 2nmis have 3). For the MCAR
situation, the missingness of Arm 3 and Arm 1 are determined by logit(pmisi3 ) = 1 and
logit(pmisi1 ) = −1 respectively. For the MAR situation, the missingness of Arm 3 is de-
termined by logit(pmisi3 ) = 1+logit(
yi2
n ), whereas the missingness of Arm 1 is determined
by logit(pmisi3 ) = −1− logit(yi2n ). Note that in missing data simulations it is a common
approach to generate complete data first and then randomly delete some, leaving the
missing percentage unknown. We instead first decide how many trials will be deleted
and then select these trials according to pmisi3 and p
mis
i1 until the pre-determined number
of missing trials is satisfied. In this way, we are able to track the model performance
under various missing percentages.
Simulation 2 We now assess the influence of nonignorable missingness (MNAR).
For simplicity, we generate data according to MOI iii, which is the best model of interest
for the smoking cessation data set. We let the true mean parameters be µ1 = −1.4, µ2 =
−1.0, and µ3 = −0.8, standard deviance σ = 0.4, and correlation coefficient ρ = 0.5; pik
and yik are then generated accordingly. The true odds ratios are OR21 = 2.00, OR31 =
2.77, and OR32 = 1.38 correspondingly. We assume Arm 1 and Arm 3 are observed
and the probability of missingness for Arm 2 is dependent on the unobserved values
themselves yi2 through formula logit(p
mis
i2 ) = 1 + logit(
yi2
n ), which leads to nonignorable
missingness.
3.3.2 Simulation results
Simulation 1 Figure 3.2 presents bias and MSE of ORs (OR21, OR31, and OR32)
obtained from the AB method and the CB method under both MCAR and MAR mech-
anisms. Bias from our proposed AB method is consistently smaller than 0.05 for all
nmis = 10, 11, 12, 13, or 14 under both mechanisms, where bias from the CB method
sometimes is bigger than 0.05 (see the two plots in the left column of Figure 3.2). Under
both MCAR and MAR mechanisms, MSE from our AB method (the right column of
Figure 3.2) is consistently smaller than from that of CB method for different nmis values.
This suggests that our method is less biased than the CB method. Another phenomenon
we observe in Figure 3.2 is that the difference between two methods is smaller when
the number of missing trials is small, e.g. when nmis = 10 and 11. However, when nmis
becomes bigger, e.g. 12, 13, and 14, which mimics the real smoking cessation data, our
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Figure 3.2: Bias and MSE under MCAR and MAR mechanisms
AB method is more robust to the missing data. In general, our proposed AB method
outperforms the existing CB method in terms of bias and MSE under both MCAR and
MAR assumptions.
Simulation 2 Our investigation of the influence of nonignorable missingness is
based on fitting 5 models (MMAR, MMNAR1, MMNAR2, MMNAR3, and MMNAR4) to the
simulated dataset which contains nonignorable missingness. MMAR is set to be exactly
MOI iii, which ignores the nonignorable missingness. MMNAR1 uses MOI iii as the
model of interest and sets the parameter of missingness equal to 0, i.e., logit(pmisi2 ) =
α0 + 0 ∗ logit(pi2), thus it is actually equivalent to the MMAR model. For MMNAR2,
both parts of the model are correctly specified, i.e., MOI iii for model of interest, and
logit(pmisi2 ) = α0 + α1 ∗ logit(pi2) for model of missingness (Note that the estimated
posterior pi2 is an approximation for
yi2
n ). MMNAR3 and MMNAR4 have overly complex
forms for missingness, i.e., logit(pmisi2 ) = α0 + α1 ∗ logit(pi2) + α2 ∗ p2i2 and logit(pmisi2 ) =
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α0 + α1 ∗ logit(pi2) + α2 ∗ logit(pi1) respectively, jointly modeled with MOI iii. In
general, MMNAR2, MMNAR3, and MMNAR4 take nonignorable missingness into account,
while MMAR and MMNAR1 disregard nonignorable missingness.
Table 3.3 provides evidence that ignoring nonignorable missingness will lead to bias.
MMAR and MMNAR1 produce both larger relative bias and MSE, for the estimation of
OR21 and OR32, compared with the true MMNAR2 and overly complex MMNAR3 and
MMNAR4. Relative bias is defined as bias divided by the true value. For example, the
relative bias for OR21 is -0.11 from both MMAR and MMNAR1, while it is only -0.04
from MMNAR2 and MMNAR3, and -0.08 from MMNAR4. Now let us take the OR32 as an
example, the MSE is 0.11 from MMAR and MMNAR1, in contrast to 0.07 from MMNAR2
and MMNAR3 and 0.10 from MMNAR4. In a nutshell, joint models MMNAR2, MMNAR3, and
MMNAR4 incorporating nonignorable missingness do outperform MMNAR1 and MMAR,
though misspecification of the missingness may slightly affect the model performance
as MMNAR4.
Another phenomenon we observe in Table 3.3 is that the relative biases and MSEs
for OR31 from all models are the same, which is because Arm 1 and Arm 3 are fully
observed. Therefore though our proposed method aims to tackle missing data in NMA,
especially nonignorable missingness, it is robust even if there is no missingness. Note
that in all joint models the relative biases for OR31 are all around 0, while relative biases
for OR21 and OR32 are slightly bigger than 0, partly due to the noninformative priors
for the missingness parameters.
In summary, when nonignorable missingness is present, our selection model method
provides an effective solution.
3.4 Discussion
Although clinical and policy-making interest often lies in comparing active agents, new
drugs are often compared with placebo or standard treatments in order to obtain ap-
proval for drug licensing [98]. Thus it is unrealistic to expect that comparisons of all
treatments of interest will be provided from any single trial as the licensed and reference
treatments can differ across countries and over time. Network meta-analysis, if properly
applied, can serve decision-making as a better tool than pairwise meta-analysis [99] and
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bring tremendous changes to the practice of evidence-based medicine.
Selective choices of treatments and trials may lead to MNAR. Neither the current
CB method, assuming MCAR, nor the AB method [8], assuming MAR, can handle this
thorny situation. We extended the AB method in Chapter 2 to incorporate nonignorable
missingness using sensitivity analysis, and evaluated its performance through simula-
tions. In addition, we have also shown with simulation studies that the AB method
outperforms the current CB method in terms of both bias and MSE.
Though other methods exist for sensitivity analysis, selection models are intuitively
appealing because they show how the probabilities of missingness depend directly on
the data values and their factorization specifies f(Yobs, Ymis|θ) directly, which is the
distribution that analysts are usually interested in. However, selection models rely
heavily on the correct specification of the model form[59]. Alternatively, pattern-mixture
models, which do not require correct specification of the precise model form (albeit with
their own limitations), should be considered as well to handle nonignorable missingness.
Important limitations for all NMA methods include inconsistency and publication
bias. Inconsistency, defined as apparent discrepancy between direct and indirect com-
parisons of two treatments, is one of the major issues in NMA. The extensive criticism
of network meta-analysis is associated with the difficulty in evaluating the assumption
underlying the statistical synthesis of direct and indirect evidence. Methods assessing
inconsistency have their own drawbacks and some of them are cumbersome to apply.
Publication bias, the concern that studies with significant results are more likely to
be published and published studies are more likely to be included in meta-analysis, is
another potential source of bias[28] in NMA. Approaches that test as well as account
for inconsistency and publication bias await further exploration.
Although researchers recognize the benefits of NMA, they often use indirect evidence
as a second choice, giving priority to direct evidence to inform decision making. Overall,
many health care practitioners remain skeptical of this emerging statistical technique.
The assumption underlying the models, the statistical expertise required to fit them,
the issues of inconsistency and publication bias, and the lack of an interpretable and
simple measure to summarize the results and to evaluate the risk of bias contribute
to this skepticism. Future research should focus on interpretation and applicability in
addition to more imaginative statistical modeling.
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Table 3.1: Smoking Cessation Data (yik/nik)
Baseline Study A B C D
A 1 9/140 23/140 10/138
2 79/702 77/694
3 18/671 21/535
4 8/116 19/146
5 75/731 363/714
6 2/106 9/205
7 58/549 237/1561
8 0/33 9/48
9 3/100 31/98
10 1/31 26/95
11 6/39 17/77
12 95/1107 134/1031
13 15/187 35/504
14 78/584 73/675
15 69/1177 54/888
16 64/642 107/761
17 5/62 8/90
18 20/234 34/237
19 0/20 9/20
B 20 20/49 16/43
21 11/78 12/85 29/170
22 7/66 32/127
C 23 12/76 20/74
24 9/55 3/26
Note: yik is the number of events and nik is the total
number of subjects.
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Table 3.2: Posterior summaries of population-averaged event rates for smoking cessation
data
MOI i MOI ii MOI iii MOI iv MOI v JM i JM ii
piA
0.11 0.10 0.09 0.08 0.08 0.09 0.09
(0.08,0.15) (0.08,0.13) (0.06,0.12) (0.06,0.11) (0.06,0.10) (0.06,0.13) (0.06,0.12)
piB
0.13 0.17 0.14 0.16 0.15 0.13 0.15
(0.09,0.18) (0.11,0.27) (0.09,0.22) (0.09,0.33) (0.09,0.24) (0.07,0.22) (0.09,0.24)
piC
0.18 0.25 0.18 0.18 0.17 0.18 0.18
(0.14,0.24) (0.16,0.39) (0.14,0.23) (0.13,0.24) (0.13,0.23) (0.14,0.24) (0.14,0.23)
piD
0.20 0.31 0.21 0.23 0.21 0.20 0.22
(0.14,0.27) (0.18,0.50) (0.14,0.32) (0.13,0.45) (0.13,0.33) (0.11,0.33) (0.14,0.34)
DICM —– —– —– —– —– 104.1 109.2
DICI 545.50 374.9 323.1 325.5 324.4 323.2 323.1
Posterior medians and their 95% credible intervals.
The bold and italic cell shows the smaller DIC.
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Table 3.3: Performance of joint modeling when MNAR is present
OR21 OR31 OR32
ReBias
MMAR -0.11 0.01 0.16
MMNAR1 -0.11 0.01 0.16
MMNAR2 -0.04 0.01 0.08
MMNAR3 -0.04 0.01 0.08
MMNAR4 -0.08 0.01 0.11
MSE
MMAR 0.14 0.18 0.11
MMNAR1 0.14 0.18 0.11
MMNAR2 0.13 0.18 0.07
MMNAR3 0.13 0.18 0.07
MMNAR4 0.13 0.18 0.10
MMAR: MOI iii & NA
MMNAR1: MOI iii & logit(p
mis
i2 ) = α0 + 0 ∗ logit(pi2)
MMNAR2: MOI iii & logit(p
mis
i2 ) = α0 + α1 ∗ logit(pi2)
MMNAR3: MOI iii & logit(p
mis
i2 ) = α0 + α1 ∗ logit(pi2) + α2 ∗ p2i2
MMNAR4: MOI iii & logit(p
mis
i2 ) = α0 + α1 ∗ logit(pi2) + α2 ∗ logit(pi1)
ReBias = Bias
True Value
Chapter 4
The effects of excluding trials
from network meta-analyses
Mills et al. [58] showed empirically that excluding treatments in NMA sometimes can
have important effects on treatment effect estimates. In this chapter, we instead obtain
empirical evidence on whether selective inclusion of trials can impact treatment effect
estimates in an NMA setting, using both the AB and CB methods. Section 4.1 describes
the source of data as well as their extraction, and the reanalysis strategy. Section 4.2
presents the analyzed networks, shows the impact of removing trials, and compares the
performance of the AB and CB methods in terms of impact. We conclude this chapter
with discussions of limitations and future work in Section 4.3.
4.1 Materials and Methods
Data source and data extraction
The data sets come from a paper by Veroniki et al. [1] evaluating inconsistency in NMAs.
The authors searched in PubMed for research articles published between March 1997
and February 2011 including networks of at least four treatments, one closed loop and
dichotomous primary outcomes. After some screening process they ended up with 40
networks. Then they extracted data regarding the year of publication, the methods
applied for indirect comparison, the number of studies, and the number of arms the
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studies included, as well as the total number of interventions involved in each network.
The extracted trial data include the name of each trial, the number of events, the sample
size and the treatment in every arm.
We gained the data of these 40 networks from the authors of this paper [1] and
now present them in Table 4.1. nt represents the total number of treatments of interest
in each NMA. Due to identifiability issue, we require that each treatment has been
compared in at least 3 trials in each network, which will be explained in the next
section. nt3 records the number of treatments that are compared in less than 3 trials.
nt3 = 0 indicates all treatments included in the NMA have been compared in at least
3 trials; while nt3 6= 0 suggests some treatments appear less than 3 times in this NMA.
We delete all NMAs whose nt3 6= 0, and finally end up with 14 networks showed in bold
cells in Table 4.1.
Statistical analysis
For each of the 14 NMAs, we firstly analyzed the complete available data with both the
AB and the CB methods and recorded the treatment effect estimates for all pairwise
comparisons. Then we performed reanalysis excluding one trial every time and esti-
mating corresponding estimates with the remaining trials. To evaluate the impact of
exclusion of trials on estimation, we calculated the absolute relative changes (ARC) of
the estimates. For example, if an estimated OR is 0.90 in the full network and 0.75 in
the network with one trial excluded, then the ARC is |(0.75−0.90)/0.90| = 0.17. We ap-
plied both AB and CB methods to investigate and compare relative changes regardless
of the analyses chosen in the original publications.
We now present the two categories of model parameterizations. We first briefly
show the AB method proposed in Chapter 2 Section 2.2.2, but in a simpler format, as
Φ−1(pik) = µk + σkνik, where νik ∼ N(0, 1). Then the population-averaged event rate
for treatment k has a closed form as pik = E(pik|µk, σk) =
∫∞
−∞Φ(µk + σkz)φ(z)dz =
Φ(µk/
√
1 + σ2k), k = 1, . . . ,K. The marginal ORs are then defined as ORkl = [pik/(1−
pik)]/[pil/(1− pil)] for a pairwise comparison between treatments k and l (k 6= l). In this
model, µk and σk are the two parameters of interest for each treatment k. Thus in order
to be identifiable, at least 2 trials are required for each treatment. In other words, we
need to make sure each treatment in an NMA has been compared in at least 2 trials.
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And since we delete a trial in each reanalysis, we select NMAs whose treatments have
been compared in at least 3 trials as is shown in Table 4.1. Though the AB method
focuses on estimating event rate for each treatment arm, we use OR as the reporting
scale in this paper in order to be consistent with the CB method.
We then present the CB method proposed by Lu & Ades [17] on the following
hierarchical structure, which is in a more general form than the method in Section
2.2.1:
logit(pik) = µk +Xikδib(i)k,
δib(i)k,k∈Si |d, V ∼MVN(d, V|Si|−1),
where vector δib(i)k,k∈Si has a multivariate normal distribution with mean vector d =
(db(i)k) and covariance matrix V|Si|−1 if the ith trial is a multi-arm comparison or an
univariate normal distribution if the ith trial is a two-arm comparison. Si is the cardi-
nality of trial i. A very common V|Si|−1 is a homogeneous-variance exchangeable matrix
with correlation 1/2, i.e., δib(i)k ∼ N(db(i)k, σ2) and cov(db(i)k, (db(i)h) = 1/2σ2. The
model also assumes exchangeability, i.e., dhk = dbh − dbk. Finally ORhk = edhk .
Analyses were conducted using WinBUGS version 1.4 (Medical Research Council
Biostatistics Unit, Cambridge) and R version 3.0.2 (www.r-project.org/).
4.2 Results
Analyzed networks
The 14 networks with individual trial data involving 567 randomized controlled trials
with 389361 patients are shown in more details in Table 4.2. It presents the names of
the 14 NMAs, the total number of studies and nodes (i.e., treatments of interest) in
each NMA and the outcome investigated in each evidence synthesis. Networks ranged
in size from 9 trials on 4 treatments to 111 trials on 12 treatments. Note that here 9
trials on 4 nodes does not conflict with the ≥ 3 criteria since some trials are multi-arm
where multiple treatments (> 2) are compared. Thus the condition that each treatment
is compared in at least 3 trials is still satisfied.
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Changes after removal of trials(
K
2
)
= K(K−1)2 ORs were estimated in an NMA involving K treatments, thus
K(K−1)
2
ARCs were calculated with the estimates obtained before and after removal of a trial.
We record the maximum and mean of the ARCs after removing of each trial. Suppose
we have I trials in an NMA, then I maximums and I means are recorded.
Figure 4.1 presents these maximums and means. The left plot shows the maximum
ARCs obtained from the CB method (y-axis) versus these obtained from the AB method
(x-axis). Dots of different colors are from different networks. Maximum ARCs are
mostly within 0.2, but up to 0.64 for the CB method and 0.53 for the AB method. The
red fitted regression line is slightly above y = x, which suggests removal of trials causes
slightly larger maximum ARCs from the CB method than the AB method. The right
plot is for mean ARCs. Most points are within 0.1, while they are up to 0.31 for the
CB method and 0.26 for the AB method. Though the red regression line is still slightly
above the y = x line, difference between these two lines are very small. It seems the CB
method is well-matched with the AB method using mean ARC as the standard measure.
In short, exclusion of trials can sometimes have large impact on results.
Comparison of AB versus CB method
We investigated further the difference in robustness of the two methods in terms of
impact when deleting a trial. A paired t-test comparing the maximum ARCs from the
AB method with those from the CB method produced a p-value 0.56, showing that there
were no statistically significant differences between the two methods. Similar analysis
of mean absolute relative changes with p-value 0.69 drew the same conclusion.
Figure 4.2 is a Bland-Altman plot [109][110][111], which is often used to analyze the
agreement between two different methods. In this plot, instead of using relative changes,
we used differences of ORs in the log scale. The log OR differences obtained from the
AB and CB methods are denoted as logORAB
OR(i)AB
and logORCB
OR(i)CB
, where i represents the
deleted trial. In Figure 4.2, the x-axis shows the mean of the log OR changes obtained
from the two methods 12(log
ORAB
OR(i)AB
+ logORCB
OR(i)CB
) , while the y-axis shows the difference
of the log OR changes from the two methods logORAB
OR(i)AB
− logORCB
OR(i)CB
, which are defined
as bias in Bland-Altman plot. The dashed gray line Figure 4.2 shows that the mean
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Figure 4.1: Scatter plot for maxmium and mean absolute relative changes in ORs
comparing AB method with CB method. Different colors represent different networks.
The red lines are the regression lines, and the black dash lines are the identical lines
y = x.
bias is very close to 0, indicating the average discrepancy between methods is not large
enough to be important. The solid gray lines representing the limits of agreements are
relatively narrow, suggesting the two methods are essentially equivalent. In addition,
the scatter points of difference do not show any particular pattern, suggesting that there
is no systematic difference between the two methods.
4.3 Discussion
It is common for network meta-analysis to exclude trials and specific treatment arms
based on widely diverse criteria [58]. The empirical impact in exclusion of treatments
arms was investigated in Mills et al. [58], while the impact in exclusion of trials has
not been previously discussed. In this chapter, we documented that exclusion of trials
can have significant impact on results. Although exclusion of a particular trial does not
affect the treatment effect estimates much in traditional meta-analyses [112][113], our
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results do find that some exclusions can affect substantially the estimated treatment
effects. We also find the performance of the AB and CB methods are similar.
Of course, caveats to our analysis exist. Firstly, it is not practical for us to retrieve
the trials that had been excluded up front and evaluate the impact of their inclusion.
Instead, the potential impact that further exclusions may bring was investigated in this
paper. Secondly, although we suggest inclusion of all trials possible, we acknowledge that
this is daunting in practice due to unavailability and high expense. Thirdly, sometimes
certain exclusions are clearly justifiable; e.g., inclusion of poorly designed trials may
instead lead to bias, which is broadly related to the outlying trials.
Turning to future work, we are interested in developing methods for handling pub-
lication bias, the concern that studies with significant results are more likely to be
published, and published studies (especially those in the meta-analysts own language)
are more likely to be included in an NMA. There have been various methods developed
for publication bias in traditional meta-analyses, but few previous papers have consid-
ered methods for handling publication bias in NMA framework. Our future interest
also lies in quantifying characteristics of the trials whose removal would bring more
significant impact on the estimation. This research has a potential to serve as guidance
for future network meta-analysis.
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Table 4.1: 40 network meta-analyses from Veroniki et al. [1]
Network number
nt3
nt
Network number
nt3
nt
1 5/9 21 1/4
2 0/5 22 0/4
3 2/8 23 0/4
4 0/4 24 3/11
5 1/8 25 0/8
6 2/8 26 2/5
7 3/7 27 2/7
8 1/6 28 0/5
9 0/4 29 8/11
10 0/12 30 6/10
11 2/9 31 1/5
12 0/5 32 1/8
13 0/6 33 5/8
14 1/5 34 0/5
15 1/4 35 0/4
16 4/13 36 2/5
17 1/5 37 2/9
18 4/9 38 9/16
19 0/4 39 4/10
20 0/6 40 1/6
Note: nt represents the number of treatments in each NMA,
while nt3 represents the number of treatments that have
been compared in less than 3 trials. Bold cells have nt3 = 0.
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Table 4.2: 14 network meta-analyses we analyzed
Author name # studies # nodes Condition/outcome
Ara 2009 [100] 11 5 Hypercholesterolaemia/Discontinuation
due to adverse event
Ballesteros 2005 [101] 9 4 Dysthymia
Bucher 1997 [102] 18 4 Pneumocystis carinii
Cipriani 2009 [34] 111 12 Unipolar major depression in adults/
response to treatment
Eisenberg 2008 [103] 61 5 Smoking
Elliott 2007 [36] 22 6 Hypertension, high risk patients/patients
who developed diabetes
Lu.1 2009 [80] 24 4 Smoking cessation
Lu.2 2007 [79] 40 6 Gastroesophageal reflux disease
Middleton 2010 [104] 20 4 Heavy menstrual bleeding
Mills 2009 [105] 89 4 Short-term smoking abstinence
Picard 2000 [106] 43 8 Pain on injection
Puhan 2009 [107] 34 5 COPD
Thijs 2008 [108] 23 5 Serious vascular events after transient
ischaemic attack (TIA) or stroke
Trikalinos 2009 [46] 62 4 Non-acute coronary artery disease
Note: The author names of the 14 NMAs, the number of studies and nodes in
each network and the outcomes.
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Figure 4.2: Bland-Altman Plot. The difference between log OR changes obtained from
AB method and CB method is drawn against the mean of the log OR changes obtained
from the two methods. Dash line represent the mean of bias, and the solid lines show
the limits of agreement.
Chapter 5
Detecting outlying trials in
network meta-analysis
Some trials may appear to deviate markedly from the others, and thus be inappropriate
to be synthesized in an NMA. In addition, the inclusion of these trials in evidence
synthesis may lead to bias in estimation. We call such trials trial-level outliers. In this
chapter, we introduce two NMA model frameworks for Gaussian data (contrast-based
and arm-based) in Section 5.2 and propose four Bayesian outlier detection measures in
Section 5.3, which are then applied to a diabetes data set introduced in Section 5.1. The
corresponding data analysis results are shown in Section 5.4, and the performance of
the method is evaluated through simulation studies in Section 5.5. We end this chapter
with a discussion and further model extension suggestions in Section 5.6.
5.1 Illustrative diabetes data
The diabetes network meta-analysis shown in Table 5.1 comprises efficacy responses
over 12 internal industry-sponsored trials of 5 potential diabetes treatments (1: PIO
(pioglitazone), 2: Placebo, 3: MET (metformin), 4: SU (sulfonylurea), and 5: ROSI
(rosiglitazone)). The major efficacy outcome is the mean change in HbA1C (denoted by
“mean” in Table 5.1), which is a lab measurement indicating the average level of blood
sugar (glucose) over the previous 3 months, and is thought of as a measure of how well
a patient is controlling his or her diabetes. The columns “n” and “sd” in Table 5.1
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Table 5.1: Diabetes dataset
1 (PIO) 2 (Placebo) 3 (MET) 4 (SU) 5 (ROSI)
Trials n mean sd n mean sd n mean sd n mean sd n mean sd
1 103 -0.76 0.97 115 -0.16 0.92
2 248 -0.91 1.53 56 0.65 1.27
3 73 -1.02 1.46 13 -1.10 1.63
4 131 -1.03 1.57 65 0.66 1.38
5 285 -1.25 1.15 138 -0.38 1.05
6 379 -0.17 1.31 193 -1.06 1.67
7 124 -0.26 0.58 441 -0.41 0.54 145 -0.35 0.49
8 533 -1.59 1.15 539 -1.79 1.13
9 551 -1.66 1.01 541 -1.84 1.12
10 283 -1.28 0.97 275 -1.4 0.98
11 51 -1.07 1.36 56 -1 1.03
12 41 -1.11 1.32 38 -0.78 1.21
Note: n denotes sample size; mean denotes sample mean; sd denotes standard
sample deviation.
represent sample size and sample standard deviation, respectively.
Figure 5.1 is an undirected graph elucidating the network of comparative relations
for the 5 drugs in our NMA. Every node has different size, indicating the total sample
size randomized to each treatment, and every edge has different thickness, indicating
the frequency of each comparison (i.e., the number of studies including this pair of
treatments). Seven trials (Trials 1-7) include comparisons of PIO versus Placebo, 4
trials (Trials 9-12) include comparisons of PIO versus SU, 1 trial (Trial 8) compares
MET and PIO, and 1 trial (Trial 7) compares PIO, ROSI, and Placebo.
5.2 Statistical models for NMA of continuous data
In this section, we present two NMA model parameterizations (AB method and CB
method) for Gaussian data.
Arm-based method: Chapter 2 proposed an arm-based NMA model for binary
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Figure 5.1: Graphical representation for the network of the diabetes dataset. The size
of each node is proportional to the sample size randomized in each treatment, and the
thickness of the link is proportional to the numbers of trials investigating the relation
data. Here we modify this model to adapt to the Gaussian diabetes data as follows:
yik ∼ N
(
∆ik,
σ2
nik
)
Sd2ik ∼ Gamma
(
nik − 1
2
,
nik − 1
2σ2
)
and ∆ik = µk + γνik,
(5.1)
where the observations yik (most often thought of as group means yik =
1
nik
nik∑
j=1
yikj)
represent the mean response change of HbA1C over nik patients assigned to the k
th
treatment in the ith trial. This response is assumed to have a normal distribution with
mean ∆ik and variance
σ2
nik
, where ∆ik and σ
2 are the true population mean and variance.
Sd2ik is the group-level sample variance, which then has a Gamma distribution with scale
parameter nik−12 and rate parameter
nik−1
2σ2
. Finally, µk is the treatment-specific fixed
effect and γ is the standard deviation of ∆ik, implemented via a random effects νik
independently distributed as standard normal. Since γ is the same across k, (5.1) is a
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homogeneous-variance model. If we instead use γk, we obtain a heterogeneous-variance
model.
Note that in (5.1), Sd2ik =
1
nik−1
∑nik
j=1(yikj − yik)2 is the sample variance of nik
observations, where j represents the subject. Thus by Basu’s Theorem, yik and Sd
2
ik
are statistically independent, and
(nik−1)Sd2ik
σ2
∼ χ2(nik − 1) ≡ Gamma(nik−12 , 12). This
in turn implies that Sd2ik ∼ Gamma(nik−12 , nik−12σ2 ).
Contrast-based method: Following Spiegelhalter et al. [114] and Ding and Fu
[115], a contrast-based network meta-analysis model for Gaussian data can be written
as ∆ik = ∆i + Xikδibk with δibk
ind∼ N(dbk, 2). Here, Xik is an indicator taking value
0 when k = b and value 1 when k 6= b, ∆i is the baseline mean response for the ith
trial, and δibk measures the effect of treatment k relative to the baseline treatment
b, which is permitted to change across studies. Note that when Xik = 0, ∆ik = ∆i
represents the response in the baseline group in the ith trial. dbk is the mean contrast
effect of treatment k versus b, and 2 is the variance. Here yik and Sd
2
ik have the same
distribution as in (5.1), i.e., yik ∼ N(∆ik, σ2nik ) and Sd2ik ∼ Gamma(
nik−1
2 ,
nik−1
2σ2
). Again,
this model is a homogeneous-variance model, while δibk ∼ N(dbk, 2bk) corresponds to a
heterogeneous-variance model.
The comparison between the arm-based method and the contrast-based method has
been previously discussed [8][116]. In this paper, we will only focus on the arm-based
method, though our methods could apply equally well to the contrast-based setting (and
might well identify different outlying studies in that case).
5.3 Outlier detection measures
5.3.1 Relative distance
We define cross-validatory (or “leave one out”) relative distance statistics, RDki , to
measure the effect of deleting trial i on our NMA estimate for a particular treatment k
as
RDki =
∣∣∣∣ ηˆk − ηˆk(i)ηˆk
∣∣∣∣ , (5.2)
where ηˆk is some estimate of interest (e.g., the posterior mean treatment effect) for
treatment k from the full data, and ηˆk(i) is the estimate for treatment k from the data
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where trial i has been omitted. The bigger RDki is, the higher the relative effect of
deleting trial i is, and thus the higher the likelihood that trial i is influential and may
be a “trial-level outlier” in this sense. We can also define an average relative distance
(ARD) to measure the average effect of deleting trial i as:
ARDi =
1
K
K∑
k=1
∣∣∣∣ ηˆk − ηˆk(i)ηˆk
∣∣∣∣ , (5.3)
where ηˆk and ηˆk(i) have the same representations as in (5.2). The bigger the ARDi is,
the greater the average effect of deleting trial i is. We may define trial i as an outlier if
RDki or ARDi is large relative to the full collection of values. Formal “probabilities of
being an outlier” could also be computed; say, P (RDki > T|data) for some preselected
threshold T, say T = 0.1.
5.3.2 Standardized trial residuals
Again, based on cross-validatory thinking, we might calculate the fitted value for yik by
conditioning on all data except yi, namely, y(i) = (y1, . . . ,yi−1,yi+1, · · · ,yI)′, where
yi = {yi,k, k ∈ Si} and Si represents the set of treatments compared in trial i. We then
compute the difference between the observed and fitted values for yik and standardize
it as follows:
STRki =
yik − E(yik|y(i))√
V ar(yik|y(i))
, (5.4)
where the STRki stands for the Bayesian standardized trial residual for the k
th treatment
in the ith trial. The average absolute standardized trial residual (ASTR) can be defined
correspondingly as:
ASTRi =
1
nSi
∑
k∈Si
∣∣∣∣∣∣yik − E(yik|y(i))√V ar(yik|y(i))
∣∣∣∣∣∣ , (5.5)
where Si has the same representation as before, and nSi represents its cardinality. Large
STRki and ASTRi, say larger than 1.5, suggest observation yik and trial i may be outliers
respectively. Note that in formulas (5.4) and (5.5), we compute the posterior mean and
variance with respect to the conditional predictive distribution,
f(yik|y(i)) =
f(y)
f(y(i))
=
∫
f(yik|θ,y(i))p(θ|y(i)) dθ,
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where θ is the entire parameter collection. In other words, f(yik|y(i)) is the posterior
predictive density of yik given the remainder of the data except that concerning trial i.
5.3.3 Bayesian p-value
An alternative to cross-validatory approaches as described in Sections 5.3.1 and 5.3.2 is
the use of posterior predictive model checks, an approach initially promoted by Rubin
[117] and popularized by Gelman et al. [118]. The key idea is to construct some “discrep-
ancy measures” that capture departures of the observed data from the assumed model
(likelihood and prior distribution). Note that though such measures must be functions
of observed data alone in the classical frequentist framework, Bayesian model checking
based on posterior predictive distributions allows more general measures that depend
on both data and parameters. Gelman et al. (1996) suggest an omnibus goodness of fit
discrepancy measure Dki (yik,θ) that depends on the parameters θ and the data yik,
Dki =
[yik − E(Yik|θ)]2
V ar(Yik|θ) .
We subsequently define an average discrepancy measure ADi(yi,θ) as
ADi =
∑
k∈Si
[yik − E(Yik|θ)]2
V ar(Yik|θ) ,
where of course θ varies according to its posterior distribution, and Si is the set of
treatments that are compared in trial i. We now can compare the distribution of
Dki (yik,θ) and ADi(yi,θ) for the observed data yik and yi with that of D
k
i (y
∗
ik,θ)
and ADi(y
∗
i ,θ) for hypothetical future values y
∗
ik and y
∗
i . Note that y
∗
ik and y
∗
i are
defined as another “copy” of the observed data point yik and vector yi, which are not
observed but instead generated from their posterior predictive distributions as part of
the MCMC sampling order [119]. Dki and AD
k
i computed using the observed data that
are extreme relative to this reference distribution indicate poor model fit and merit
closer examination in the analysis.
A convenient summary measure of the extremeness of the Dki (y
∗
ik,θ) with respect to
the Dki (yik,θ) is the posterior predictive tail area, defined as the Bayesian p-value for
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discrepancy,
pDki
≡ P [Dki (y∗ik,θ) > Dki (yik,θ)|y]
=
∫
P [Dki (y
∗
ik,θ) > D
k
i (yik,θ)|θ]p(θ|y)dθ.
(5.6)
Similarly, the Bayesian p-value for average discrepancy is defined as
pADi ≡ P [ADi(y∗i ,θ) > ADi(yi,θ)|y]
=
∫
P [ADi(y
∗
i ,θ) > ADi(yi,θ)|θ]p(θ|y)dθ.
(5.7)
Note that pDki
and pADi should not be used to compare models. Rather, they serve
only as measures of discrepancy between the proposed model and the observed data,
and therefore provide information concerning overall model adequacy and outlier de-
tection. Other summaries focused on other measures of poor fit (say, in the tail of the
distribution) can also be defined; see Gelman, Meng, and Stern [120].
5.3.4 Scale mixtures of normals
The conditioning feature of MCMC computational methods enables another approach
related to models employing scale mixtures of normals (SMN) (see [119], p.184) to
investigate outlyingness. Here we expand model (5.1) to
yik ∼ N(∆ik, λi σ
2
nik
), (5.8)
where the λi are unknown scale parameters. We then specify prior distributions for λi,
for example,
SMN1 : λi ≡ 1⇒ Normal errors
SMN2 : λi ∼ IG
(
υ
2
,
2
υ
)
⇒ Students’ tυ errors
and SMN3 : λi ∼ Expo(2)⇒ Double exponential errors,
where the distributions behind the arrow symbols identify the possible departures from
normality for the error terms. Since extreme observations will correspond to extreme
fitted values of these scale parameters λi, potential outliers can be identified by examin-
ing the λi posterior distributions. Doubt is cast on the commensurability of trial i with
the rest if the posterior mean (or median) of λi is much bigger than 1, or if P (λi ≥ 1|y)
is larger than some threshold value, say 0.95.
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5.4 Application to diabetes data
5.4.1 Outlier detection results with various measures
Relative distance
We first fit model (5.1) to our diabetes NMA data and record the posterior estimates.
Then we fit model (5.1) 12 more times with the 1st through 12th trials omitted, re-
spectively, and record all necessary posterior estimates. Finally, we calculated RDki
according to (5.2) with µˆk obtained from the full data and µˆk(i) obtained from the data
with the ith trial deleted. Note that here we let ηˆk = µˆk, the mean treatment effect,
when we calculate RDki . ARDi is calculated similarly.
Figure 5.2 shows the relative distances separately for the 5 treatments (PIO, Placebo,
MET, SU, and ROSI). The vertical axes show relative distances ranging from 0.0 to 1.0,
and the horizontal axes index trials that are deleted in the calculation of the relative
distances. Thinking of 0.2 as a significance threshold, Trial 6 is mildly influential for
PIO; Trials 2, 4, 6 are influential for Placebo; Trial 8 is influential for MET; Trials 6
and 9 are mildly influential for SU; and Trials 2, 4, 6, and 7 are influential for ROSI.
Note that Trials 2, 4, and 6 are influential for ROSI even though they do not directly
compare this treatment. In short, with 0.2 as the cutoff for RDki , Trials 2, 4, 6, 7, and
8 seem to be potential outliers.
Figure 5.3 shows the average relative distances. ARDi for i = 6, 7, and 8 are above
threshold T = 0.1, while those for the others are below this level (though some only
narrowly). Thus Trials 6, 7, and 8 are more influential with ARDi as the evaluation
criteria. This is roughly consistent with the results in Figure 5.2.
We further investigate the possibility that Trials 2, 4, 6, 7, and 8 are outliers. First,
it seems fair to call Trials 2 and 4 outliers since the mean change values of HbA1C for
patients treated with Placebo are all negative except in these two trials. Second, for
Trials 6 and 7, the mean change values of HbA1C for patients treated with PIO from
both trials are much smaller than those from the other 10 trials. Thus Trials 6 and 7 are
extreme in this sense. Third, the mean HbA1C change responses for patients in Trial
8 do not seem abnormal; however, we observe that MET is only contained in Trial 8,
so that deleting Trial 8 will of course have a big impact on the estimates. We thus can
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Figure 5.2: Relative distances versus deleted trials for each treatment
infer that RD38 and ARD8 for Trial 8 are big largely due to lack of information, rather
than true “outlyingness”.
Standardized trial residuals
Table 5.2 shows that the Bayesian standardized trial residuals for Trials 2, 4, and 6 are
larger than 1.5 in absolute value (more specifically, STR22 = −2.24, STR24 = −2.29, and
STR16 = −1.58). In Trials 2 and 4, the mean changes of HbA1C for patients taking
placebo are positive, while those from the other trials that contain placebo (k = 2) are
negative. Thus it seems reasonable to call Trial 2 and Trial 4 outliers. For STR16, the
Trial 6 Bayesian standardized residual for PIO (k = 1), we see that the mean change of
HbA1C for patients taking PIO in this trial is -0.17, much smaller than that from the
other trials. Thus Trial 6 would appear to highly underestimate the efficacy of PIO, i.e.,
it may also be a legitimate outlier. However, ASTR in Table 5.2 does not identify any
significant trial-level outliers, with no values larger than 1.5 and previously unidentified
Trial 9 emerging along with Trials 2, 4, and 6 with ASTR > 1.
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Figure 5.3: Average relative distances versus deleted trials
Bayesian p-values
Table 5.3 shows that Trials 2, 4, 5, 6, and 7 have at least one Bayesian p-value smaller
than 0.05. In the case of Trials 2 and 4, this is likely due to the positive responses for
placebo in these trials. By contrast, Trials 6 and 7 are likely flagged because the PIO
mean changes in HbAIC values in these two trials are much smaller than that from
the other trials, i.e., the presence of Trials 6 and 7 in the NMA would underestimate
the efficacy of PIO. Oddly, the Bayesian p-values for Trial 5 are also smaller than 0.05,
an apparent significance that may be inflated by small variances and merits further
investigation. At any rate, it suggests the omnibus goodness of fit measure adopted in
Section 4.3 may not be optimal in this particular setting.
Scale mixtures of normals
Figure 5.4 shows that Trials 2, 4, 6, and 7 once again emerge as outliers under both
models SMN2 and SMN3, since the posterior estimates for the scale parameters λi are
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Table 5.2: Results for Bayesian standard trial residuals
Trial Treatment STR ASTR Trial Treatment STR ASTR
1
1 -0.35
0.64
7
1 -1.20
0.512 -0.92 2 -0.33
— — — — 5 0.00
2
1 -0.06
1.15 8
1 1.13
0.60
2 -2.24 3 0.06
3
1 0.11
0.40 9
1 1.28
1.38
2 0.69 4 1.48
4
1 0.09
1.19 10
1 0.55
0.54
2 -2.29 4 0.53
5
1 0.52
0.56 11
1 0.17
0.16
2 -0.60 4 -0.16
6
1 -1.58
1.38 12
1 0.23
0.38
2 1.18 4 -0.53
Note: Bold cells have |STR| > 1.5.
significantly larger than 1 (with their log-scale 95% CIs significantly higher than 0).
The specific estimated values of λi are listed in Table 5.4. In addition, Table 5.4 shows
that the probabilities that the scale parameters λi are larger than 1 in Trials 2, 4, 6,
and 7, are all 0.99 or greater, which further suggests the outlyingness of these trials, in
broad agreement with the results of the previous detection approaches.
5.4.2 Results with and without outliers
We compare the estimated values for parameters of interest from full data with those
computed without our identified trial-level outliers (Trials 2, 4, 6, and 7). A value
for µ5 is not computable without outliers since Trial 7, an outlier, is the only source
of information on Treatment 5 (ROSI). As shown in Table 5.5, µk estimates are quite
different before and after deleting the outliers. For example, in the case of µ2, the
relative difference is −0.67−(−0.47)−0.47 = 42.6%. Relative changes for the other µ’s are
similarly meaningful, though are less impressive for the variance parameters γ and
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Table 5.3: Bayesian p-values for discrepancy
Bayesian p-values
pD11 0.25 pD23 0.37 pD16 0.00 pD18 0.50 pD410 0.57
pD21 0.23 pD14 0.00 pD26 0.00 pD38 0.50 pD111 0.50
pD12 0.02 pD24 0.00 pD17 0.01 pD19 0.50 pD411 0.50
pD22 0.00 pD15 0.03 pD27 0.20 pD49 0.48 pD112 0.31
pD13 0.51 pD25 0.00 pD57 0.50 pD110 0.56 pD412 0.27
Note: Bold cells have p-value < 0.05.
σ2. In a nutshell, when trial-level outliers exist in an NMA, they can wield significant
influence on estimates of the parameters of interest.
5.5 Simulations
In this section we evaluate the performance of our proposed detection measures using
simulations, and demonstrate the advantages of different measures in different situa-
tions.
5.5.1 Simulation settings
We generate a continuous-data network meta-analysis with 12 trials to compare 4 treat-
ments. We set the parameters of interest according to the results of our diabetes data
analysis without outliers in Table 5.5 as follows: µ1 = −1.19, µ2 = −0.47, µ3 = −1.39,
µ4 = −1.32, and σ2 = 1.20. In order to limit the variability of the random effects, we
let γ = 0.10. For simplicity we assign nik = 100 patients to each arm k in each trial i.
Then artificial data yik can be generated according to model (5.1).
Unbalanced Design Mimicking Motivating Data: In order to make the sim-
ulated data as realistic as possible, we let Trials 1-7 compare only Arm 1 and Arm 2,
Trial 8 compare only Arm 1 and Arm 3, and Trials 9-12 compare only Arm 1 and Arm
4, again mimicking the motivating diabetes data in Table 5.1.
Balanced Design: In this setting, we still let Arm 1 be compared in all 12 trials,
but Arms 2-4 are assumed to exist in the same numbers of trials. Specifically, Trials
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Table 5.4: Results for scale mixtures of normals
λi P (λi > 1|y)
Trial SMN2 SMN3 SMN2 SMN3
1 1.57(0.30,20.06) 1.03(0.16,15.68) 0.67 0.51
2 10.22(1.89,97.33) 9.90(1.92,95.03) 0.99 0.99
3 3.11(0.67,26.84) 2.71(0.56,24.46) 0.92 0.89
4 12.71(2.52,114.50) 12.39(2.60,110.30) 1.00 1.00
5 1.69(0.29,28.37) 1.08(0.15,22.77) 0.68 0.53
6 100(24.66,788.60) 99.38(24.89,760.60) 1.00 1.00
7 24.82(4.27,222.20) 24.24(4.36,212.60) 1.00 0.99
8 1.44(0.27,36.64) 0.73(0.14,19.00) 0.63 0.40
9 1.35(0.27,19.96) 0.78(0.15,12.65) 0.62 0.41
10 1.03(0.24,11.63) 0.54(0.12,6.37) 0.51 0.28
11 1.16(0.28,10.98) 0.76(0.18,7.54) 0.57 0.39
12 2.08(0.51,18.51) 1.70(0.41,15.74) 0.82 0.74
Note: λi denotes the scale parameter; and P (λi > 1|y) denotes the
probability that the scale parameter λi is larger than 1 given the data.
Bold cells represent the outliers.
1-4 compare Arm 1 and Arm 2, Trials 5-8 compare Arm 1 and Arm 3, and Trials 9-12
compare Arm 1 and Arm 4; a simple “star network” in NMA parlance.
Finally, for both designs, we manipulate the data so that Trials 4 and 8 will be
outliers: the fixed value 5 is added to Arm 2 in Trial 4 and Arm 3 in Trial 8. We
summarize our proposed methods over 1000 simulated data sets.
5.5.2 Simulation results
For each detection measure, we compare its performance under the unbalanced and
balanced designs.
Relative distance: We show RDki for i = 1, . . . , 12 and k = 1, . . . , 4 in Table 5.6.
For the unbalanced design, most of the relative distances are close to 0 and some are
around 0.50. However, RD24 = 2.99 and RD
3
8 = 1.01, suggesting that Trials 4 and 8
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Figure 5.4: Posterior λi in log scale for SMN2 and SMN3
are influential for Arms 2 and 3, respectively, as we expected. In contrast to these
straightforward findings, the results of the balanced design are shown in the right part
of Table 5.6. RD24 = 1.60 implies that Trial 4 is influential for Arm 2; the remaining
RD2i are roughly 1/3 this magnitude (0.53). Also, RD
3
5 = RD
3
6 = 3.19, RD
3
7 = 3.20,
and RD38 = 9.58 suggests that all trials containing Arm 3 are influential for it, with
outlying Trial 8 as the most influential but the other trials again roughly 1/3 as large.
In short, relative distances can successfully detect influential trials, but the relative sizes
of these statistics can still vary over a surprising range, making a decision on cutoff value
difficult. Here, the “inflation” in values for Arm 3 appears due to the fact that µ3 is
close to 0 (-0.47). Other simulations (not shown) reveal that RD24 and RD
3
8 for the
balanced design have roughly the same magnitude if µk is constant across k.
Standardized trial residuals: Table 5.7 provides standardized trial residuals for
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Table 5.5: Posterior summaries for parameters of interest with and without outliers
µ1 µ2 µ3 µ4 µ5 γ σ2
With Outliers
-0.95 -0.67 -1.16 -1.08 -0.70 0.57 1.34
(-1.28, -0.62) (-1.01,-0.33) (-1.51, -0.80) (-1.42, -0.74) (-1.09, -0.31) (0.39, 0.86) (1.29, 1.39)
Without Outliers
-1.19 -0.47 -1.39 -1.32 —– 0.60 1.20
(-1.65, -0.71) (-0.95, 0.02) (-1.87, -0.90) (-1.78, -0.84) —– (0.38, 1.01) (1.15, 1.26)
Note that µ5 is not available in Row 2 because the only trial (Trial 7) containing
Treatment 5 is an outlier.
the 12 trials, displaying 24 values for each design. For the balanced design, STR suc-
cessfully detects Arm 2 in Trial 4 and Arm 3 in Trial 8 to be outliers. ASTR also works
as it should for the balanced design. However, for the unbalanced design, STR and
ASTR only successfully detect Trial 4, but not Trial 8. Here with only a single trial to
estimate this arm, there is no way for the procedure to identify the arm as “outlying”,
with the extra 5 units added to every simulated value simply absorbed into the mean
structure.
Bayesian p-values: We now turn to the posterior predictive model checks (Bayesian
p-values) with the omnibus goodness of fit discrepancy measure Dki (yik,θ) detailed in
Section 5.3.3. Unfortunately, as shown in Table 5.8, we find Bayesian p-values perform
poorly, with false positives common. After deeper exploration, we found the poor per-
formance was due to the discrepancy measure Dki (yik,θ) =
[yik−E(Yik|θ)]2
V ar(Yik|θ) . Hypothetical
future values y∗ik generated from their posterior predictive distributions are always very
close to E(Yik|θ), which leads to very small values of Dki (y∗ik,θ). Since the E(Yik|θ) are
not always close to the observed yik, the D
k
i (yik,θ) are mostly larger than the D
k
i (y
∗
ik,θ),
which leads to small Bayesian p-values (i.e., pDki
< 0.05). Thus as suggested earlier,
more sensible discrepancy measures appear to be needed for this approach to be feasible,
e.g., Dki (yik,θ) =
|yik−E(Yik|θ)|√
V ar(Yik|θ)
.
Scale mixture of normals: For each trial i, Table 5.9 shows the average posterior
medians of the scale parameters λ̂i, average P (λi > 1|y), and P (Positive), defined as
the empirical proportion of the 1000 simulations where P (λi > 1|y) > 0.95 (i.e., a
“positive outcome”). Under both balanced and unbalanced designs, λ̂4 is much larger
than 1, the average P (λ4 > 1|y) = 1.00 > 0.95, and P (Positive) is always equal to 1 for
Trial 4. For Trial 8, λ̂8 is much larger than 1 under the balanced design (λ̂8 = 572.50),
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Table 5.6: Relative distances for the unbalanced and balanced designs in the simulation
study
Unbalanced Design Balanced Design
Trial Arm 1 Arm 2 Arm 3 Arm 4 Arm 1 Arm 2 Arm 3 Arm4
1 0.01 0.50 0 0.01 0.01 0.53 0.05 0
2 0.01 0.50 0 0.01 0.01 0.53 0.06 0.01
3 0.01 0.50 0 0.01 0.01 0.53 0.05 0.01
4 0.01 2.99 0 0.01 0.01 1.60 0.06 0.01
5 0.01 0.50 0 0.01 0.01 0.01 3.19 0.01
6 0.01 0.50 0 0.01 0.01 0.01 3.19 0.01
7 0.01 0.50 0 0.01 0.01 0.01 3.20 0.01
8 0.01 0.03 1.01 0.01 0.01 0.01 9.58 0.01
9 0.01 0.03 0 0.01 0.01 0.01 0.06 0.01
10 0.01 0.03 0 0.01 0.01 0.01 0.05 0.01
11 0.01 0.03 0 0.01 0.01 0.01 0.05 0.01
12 0.01 0.03 0 0.01 0.01 0.01 0.06 0.01
Note: RDs bigger than 1 are in bold.
while for the unbalanced design it is only a little larger than 1 (λ̂8 = 1.33). The average
P (λi > 1|y) is 1.00 for the balanced design, but only 0.61 for the unbalanced design;
similarly P (Positive) is 1.00 for balanced Trial 8, whereas it is 0 for the unbalanced case.
The reason is that there are no other sources of information about Arm 3 in this design
except Trial 8. As in Table 5.7, the algorithm does not have any information that can
be treated as reference to detect the outlyingness of Trial 8 for Arm 3. To sum up, our
SMN measure can successfully detect trial-level outliers with very high accuracy under
a balanced replicated design, but are likely to be less effective for unbalanced designs.
In summary, our investigation with simulated data suggests that our proposed mea-
sures RD, STR, and SMN can often uncover trial-level outliers and thus facilitate more
accurate evidence synthesis. Bayesian p-values appear more dependent on a sensible
choice of discrepancy measure, and are not competitive with the other methods without
further exploration.
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Table 5.7: Standardized trial residuals for unbalanced and balanced designs in the
simulation study
Unbalanced Design Balanced Design
Trial Arm STR ASTR Trial Arm STR ASTR Trial Arm STR ASTR Trial Arm STR ASTR
1
1 0.10
0.50 7
1 0.09
0.50 1
1 0.07
0.78 7
1 0.07
0.78
2 0.90 2 0.91 2 1.48 3 1.49
2
1 0.10
0.50 8
1 0.09
0.10 2
1 0.08
0.78 8
1 0.09
2.83
2 0.91 3 0.11 3 1.49 3 5.56
3
1 0.09
0.50 9
1 0.09
0.09 3
1 0.07
0.78 9
1 0.08
0.08
2 0.91 4 0.09 2 1.49 4 0.08
4
1 0.16
4.55 10
1 0.10
0.09 4
1 0.09
2.84 10
1 0.07
0.07
2 8.94 4 0.09 2 5.59 4 0.07
5
1 0.09
0.50 11
1 0.09
0.09 5
1 0.07
0.78 11
1 0.07
0.07
2 0.90 4 0.09 3 1.48 4 0.07
6
1 0.09
0.49 12
1 0.09
0.09 6
1 0.08
0.78 12
1 0.08
0.08
2 0.90 4 0.09 3 1.49 4 0.08
Note: Cells with STR and ASTR larger than 1.5 are in bold.
5.6 Discussion and future work
Though methods for network meta-analysis have been extensively discussed and ex-
plored in the current literature, few previous papers appear to have mentioned trial-
level outliers. In this paper, we proposed four detection measures for trial-level outliers,
and applied them to a diabetes network meta-analysis, as well as simulated their per-
formance in balanced and unbalanced designs. Our results suggest RD (ARD), STR
(ASTR), and SMN perform well and are promising tools for detecting trial-level outliers.
Our detection measures can be easily extended to binary data. For example, instead
of (5.1) for Gaussian data, Zhang et al. [8] proposed an arm-based method for binary
data wherein Φ−1(pik) = µk + γνik, where pik is the event rate for the kth treatment in
the ith trial, and µk, γ, and νik have the same representations as (5.1). In this binary
data setting, RD (ARD) and STR (ASTR) can be defined similarly as in the continuous
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Table 5.8: Mean Bayesian p-values of 1000 replicates of simulations for unbalanced and
balanced designs
Unbalanced Design Balanced Design
pD11 0.03 pD19 0.58 pD25 0.02 pD11 0 pD19 0.58 pD25 0
pD12 0.03 pD110 0.58 pD26 0.02 pD12 0 pD110 0.58 pD26 0
pD13 0.03 pD111 0.58 pD27 0.02 pD13 0 pD111 0.58 pD27 0
pD14 0 pD112 0.58 pD38 0.50 pD14 0 pD112 0.58 pD38 0
pD15 0.03 pD21 0.02 pD49 0.57 pD15 0 pD21 0 pD49 0.57
pD16 0.03 pD22 0.02 pD410 0.57 pD16 0 pD22 0 pD410 0.57
pD17 0.03 pD23 0.02 pD411 0.58 pD17 0 pD23 0 pD411 0.57
pD18 0.50 pD24 0 pD412 0.57 pD18 0 pD24 0 pD412 0.57
data setting. The implementation of SMN for binary data relies on rewriting (5.1) as
Yik ∼ Bin(nik, pik), k ∈ Si, i = 1, . . . , I
where pik = P (Y
∗
ik > 0)
and Y ∗ik = µk + γνik + ik,
where the Y ∗ik are latent variables and ik
iid∼ N(0, 1); see Albert and Chib [121]. Using
this formulation, we can adapt the SMN method in Section 5.3.4 accordingly.
We acknowledge that cutoff values for detecting the practical significance of a poten-
tial outlier appear hard to select, as they can be context-, model-, and data-specific. We
have done simulations (not shown in this paper) to investigate different cutoff values for
the SMN method and found that the P (λi > c|y) varies with different predetermined
values for the cutoff c. For example, in the unbalanced design, with c = 1 as the cutoff
criterion, P (λ4 > 1|y) is 1.00 for Trial 4 but around 0.45 for the other trials, as is shown
in Table 5.9. When the cutoff value is set to be 5, however, P (λ4 > 5|y) keeps being
1 for Trial 4, but P (λi > 5|y) is around 0.06 for the other trials. If we let the cutoff
value be 10, the P (λ4 > 10|y) is again 1 for Trial 4 but around 0.02 for the other trials.
The cutoff selection issue also plagues the other measures. However, simulations like
those in Section 6 can still help guide this selection, based on the design of interest and
information content of each trial (as measured by sample sizes and variance estimates).
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Table 5.9: Scale mixtures of normals for unbalanced and balanced designs in the simu-
lation study
Unbalanced Design Balanced Design
Trial i λ̂i P (λi > 1|y) P (Positive) λ̂i P (λi > 1|y) P (Positive)
1 0.89 0.45 0 0.95 0.48 0
2 0.89 0.45 0 0.95 0.48 0
3 0.89 0.45 0 0.95 0.48 0
4 583.69 1.00 1.00 575.53 1.00 1.00
5 0.89 0.45 0 0.95 0.48 0
6 0.89 0.45 0 0.95 0.48 0
7 0.89 0.45 0 0.95 0.48 0
8 1.33 0.61 0 572.50 1.00 1.00
9 0.92 0.46 0 0.92 0.46 0
10 0.92 0.46 0 0.92 0.46 0
11 0.92 0.46 0 0.92 0.46 0
12 0.92 0.46 0 0.92 0.46 0
Note: λ̂i: the mean value of 1000 exceedance posterior medians; P (λi >
1|y): mean values of 1000 probablities that λi is larger than 1; P (Positive):
indicates probability of positive results (exceedance probability greater than
0.95) over the 1000 simulations. Bold values mark detected outlying trials.
Turning to future work, we are interested in developing methods for automatic
downweighting of outlying trials. Borrowing the idea of Ibrahim and Chen [122], power
priors offer a simple and intuitive approach, by raising the outlying likelihood to a
power α0 ∈ [0, 1], and re-standardizing the result to a proper distribution. Hobbs
et al. [123] proposed an extension called hierarchical commensurate and power priors
for adaptive incorporation of information, which could also be applied here. Future
work also looks toward extension to outlier detection for models incorporating baseline
covariates and individual-level patient data. Note that when baseline covariates are
present, the definition of outliers ought to be modified, since a trial could then be
outlying simply by having an unusual population (e.g., more older enrollees).
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Of course, criticisms of our methods can be made. In this paper, we have only
considered the trials that were already collected in an NMA. However, trials that were
candidates for inclusion but were omitted is another issue worthy of attention. This
can be broadly related to the issue of publication bias, the concern that studies with
significant results are more likely to be published, and published studies (especially
those in the meta-analyst’s own language) are more likely to be included in an NMA
[28]. Another limitation of this paper is that we have not considered arm-level outliers,
even though it may be that some treatment arms may not be suitable to be synthesized
with the others in an NMA. Approaches for these issues and their evaluation await
further exploration.
Chapter 6
Conclusions
6.1 Summary of major findings
This thesis set out to explore novel Bayesian hierarchical methods in the context of
network meta-analysis in order to provide better evidence synthesis. Our contribution
lies in providing more proper and comprehensive reporting for network meta-analysis,
which ultimately enables better decision making for patients, health carers, and policy
makers. This thesis has also sought to solve the thorny issues related to nonignorable
missingness in the highly sparse network meta-analysis data set, and when some trials in
the network are outlying. The proposed selection models method and outlier detection
measures successfully incorporates nonignorable missingness and detect outlying trials
respectively, facilitating more precise evidence synthesis.
We now summarize our findings and contributions specifically for each chapter. In
Chapter 2, we proposed a novel arm-based Bayesian hierarchical method from the miss-
ing data perspective, which focuses on estimating direct summary, i.e., event rates,
instead of relative summary, i.e., ORs. We compared its performance with the current
contrast-based method and the traditional pairwise comparison method, and illustrated
how to provide proper summaries with two published network meta-analyses. Our
method clears away obstacles for patients in order to comprehensively trade-off efficacy
and safety measures. We then built upon this method to incorporate nonignorable
missingness in Chapter 3 with the proposed selection models method. It comprises two
parts: a model of interest, and a model of missingness. Joint modeling avoided the
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bias created by ignoring missingness, or by considering all missing data to be missing at
random, verified by various simulations. Chapter 4 investigated whether removal of tri-
als had influence on the estimates of treatment effects, and gathered empirical evidence
by reanalyzing 14 published network meta-analyses after excluding specific trials. We
found that some trial exclusions can substantially affect the estimated treatment effects.
After exploring influence in exclusions of trials that should have been included, in Chap-
ter 5 we studied outlying trials that should not be included but were included. Four
Bayesian outlier detection measures were proposed and their performance was studied
via application to a diabetes data set and simulation studies.
Turning to practice, this thesis provides a practical guide on how to carry out indirect
comparisons and multiple treatment comparisons. Through a series of illustrative ex-
amples, it also showed in down-to-earth terms how to synthesize available evidence and
make better decisions using appropriate Bayesian statistical techniques. The intended
audience for this thesis is therefore mixed, including statisticians, decision makers, and
health economists. We believe people with an interest in the production of systematic
reviews will also find much that is both new and highly relevant to their work.
Of course, limitations remain. Heterogeneity and inconsistency are the two major
issues in network meta-analysis. We incorporated heterogeneity with random effects
but did not quantitatively compute it. Inconsistency was out of scope for this thesis,
although there are already a number of papers investigating it. Another limitation lies
in the approach we used for handling nonignorable missingness. After all, the selection
models method serves only as sensitivity analysis, methods searching for the particular
reason of nonignorable missingness and methods remedying it await further exploration.
Selection of cutoff values for detecting the practical significance of a potential outlier is
the third issue worthy of future efforts as these cutoff values can be context-, model-,
and data-specific.
6.2 Extensions and future work
In addition to providing immediate important findings, the work in this thesis has also
motivated a variety of future projects.
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6.2.1 NMA involving multiple type of outcomes
Future work looks to extending our method to include mixed types of outcomes, for
example, a time-to-event safety outcome paired with a binary efficacy outcome, or a
binary safety outcome paired with a continuous efficacy outcome. For example, we will
look at a network meta-analysis of HIV viral load data. Here the primary efficacy end-
point is the number of patients with HIV-RNA below the limit of assay detection (50
copies) at 48 weeks (i.e., binomial outcome), and the safety endpoint is time-to-event
disease progression or death (time-to-event outcome). Another example is a network
meta-analysis of cancer clinical trials where the tumor size serves as the efficacy end-
point (continuous outcome) while the adverse event death is the safety endpoint (binary
outcome).
6.2.2 Evidence synthesis of observational studies
There is no doubt that the RCT produces the most reliable evidence on the comparative
effectiveness of interventions; however, good, conclusive randomized evidence may not
exist for every treatment decision [124]. Thus there are occasions when it will be nec-
essary to consider observational data on which to estimate effectiveness. In other cases,
though RCTs are available, concerns regarding their quality may require supplementary
observational evidence.
When observational evidence is considered either instead of, or in combination with,
randomized evidence, the question arises as to whether we need to apply new method-
ology in order to sensibly synthesize it. Observational data potentially produce more
biased estimates than data from randomized trials. Current approaches for combining
randomized and observational evidence include deriving a prior distribution from ob-
servational evidence, bias allowance models for the observational data, and hierarchical
models with an extra level of variation to allow for variability in effect sizes between
different sources of evidence. However, these methods are all based on largely untestable
assumptions. Future investigation here are needed.
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6.2.3 Computing and software development
In order for the proposed methods to be fully embraced by researchers in non-statistical
fields, we need to provide the means which to implement them conveniently. The most
obvious way for achieving this would be by creating a freely available R package with
user-friendly functions to conduct the network meta-analysis.
For modest or slightly large sample sizes, usually at the aggregate level, it sometimes
takes a couple of hours to analyze the data. We aim to call BUGS software from R
in this situation. However, individual patient level data can be a bit computationally
burdensome. Implementing the methods to these data in BUGS and R requires much
more effort, thus we may need to develop our own package using C++ subroutines
embedded with an R wrapper.
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Appendix A
Glossary for abbreviations
CER: comparative effectiveness research.
EBM: evidence based medicine.
RCT: randomized controlled trial.
NMA: network meta-analysis.
MCAR: missing completely at random.
MAR: missing at random.
MNAR: missing not at random.
RD: risk difference.
RR: risk ratio.
OR: odds ratio.
CB: contrast-based.
AB: arm-based.
MBHMM: multivariate Bayesian hierarchical mixed model.
NICE: National Institute for Health and Clinical Excellence.
RDki : relative distance after deleting trial i for a particular treatment k.
ARDi: average relative distance after deleting trial i.
STR: standardized trial residual.
SMN: scale mixtures of normal.
ARC: absolute relative change.
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